{"question_id": "a078c0fe-eab1-4bad-b71f-46621283edb2", "source_file": "PMC10275785.json", "annotation_id": "1452143360", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.", "blanked_sentence": "Genotype _____ is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "0b54f5ac-3e68-45e0-842e-fca3d8c994de", "source_file": "PMC10275785.json", "annotation_id": "1452143360", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.", "blanked_sentence": "Genotype TT is associated with _____ response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "3621cb8a-c6c4-45b3-b9ef-e77354582c59", "source_file": "PMC10275785.json", "annotation_id": "1452143360", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.", "blanked_sentence": "Genotype TT is associated with decreased _____ etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["response to"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "4bd93668-aaac-4dba-bd9d-b2432bd368ff", "source_file": "PMC10275785.json", "annotation_id": "1452143360", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.", "blanked_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA + AT"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "84323fa7-7805-4632-8c86-88d247f425dc", "source_file": "PMC10275785.json", "annotation_id": "1452143400", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.", "blanked_sentence": "Genotype _____ is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "c6e28801-9247-4917-bcfd-ed244cf7b718", "source_file": "PMC10275785.json", "annotation_id": "1452143400", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with _____ response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "7a979c59-bf9a-47ad-9b2c-4252024fe8fa", "source_file": "PMC10275785.json", "annotation_id": "1452143400", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased _____ etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["response to"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "c38c4e8f-59e1-4ee5-80f4-bace0ea62f72", "source_file": "PMC10275785.json", "annotation_id": "1452143400", "pmid": "37332933", "original_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC + CT"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "8739a43f-575d-4996-bd45-5fe7c9df8b36", "source_file": "PMC10399933.json", "annotation_id": "1452196120", "pmid": "37490620", "original_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanked_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with _____ as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["fluvastatin"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "11634a46-425f-403a-aafb-257fab894bab", "source_file": "PMC10399933.json", "annotation_id": "1452196120", "pmid": "37490620", "original_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanked_sentence": "CYP2C9 _____ (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*2/*2 + *2/*3 + *3/*3"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "570970ba-9335-465e-b777-e07314439edf", "source_file": "PMC10399933.json", "annotation_id": "1452196120", "pmid": "37490620", "original_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanked_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with _____ risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cba10287-6cf8-4805-8613-6915c5a05bbc", "source_file": "PMC10399933.json", "annotation_id": "1452196120", "pmid": "37490620", "original_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanked_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of _____ when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Discontinuation"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1441b318-cbec-403d-844c-7def2955074f", "source_file": "PMC10399933.json", "annotation_id": "1452196120", "pmid": "37490620", "original_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanked_sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 _____ (assigned as intermediate metabolizer and normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1 + *1/*2 + *1/*3"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "59e7be38-9ddb-497d-85b4-45944bb64593", "source_file": "PMC10399933.json", "annotation_id": "1452196040", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "blanked_sentence": "Genotypes _____ is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CC + CT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "d9b82650-57f8-4e01-9dc2-3ca248c0b1d9", "source_file": "PMC10399933.json", "annotation_id": "1452196040", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is not associated with _____ risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8a21d2cc-7594-497c-8337-3f9415d580c0", "source_file": "PMC10399933.json", "annotation_id": "1452196040", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is not associated with increased risk of _____ when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Discontinuation"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "27c358b6-7350-4cac-8c52-a1dfd0c56101", "source_file": "PMC10399933.json", "annotation_id": "1452196040", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["TT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "95b0ce47-298e-47e8-9c62-b2327dc4c5a4", "source_file": "PMC10399933.json", "annotation_id": "1452196080", "pmid": "37490620", "original_sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.", "blanked_sentence": "Genotypes _____ is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["GT + TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0f237a89-5dff-43d9-b39b-e76e4e228b03", "source_file": "PMC10399933.json", "annotation_id": "1452196080", "pmid": "37490620", "original_sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.", "blanked_sentence": "Genotypes GT + TT is not associated with _____ risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2d744877-979f-4bd4-983e-353739a0b302", "source_file": "PMC10399933.json", "annotation_id": "1452196080", "pmid": "37490620", "original_sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.", "blanked_sentence": "Genotypes GT + TT is not associated with increased risk of _____ when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Discontinuation"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0251a2d5-0668-4f59-8836-e42781f9e880", "source_file": "PMC10399933.json", "annotation_id": "1452196080", "pmid": "37490620", "original_sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.", "blanked_sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["GG"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ab5207b0-0698-492e-bb73-b551d98714b6", "source_file": "PMC10399933.json", "annotation_id": "1452195940", "pmid": "37490620", "original_sentence": "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.", "blanked_sentence": "Genotype CC is associated with increased risk of discontinuation when treated with _____ as compared to genotype TT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["simvastatin"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1f60a0b1-4521-43d4-ad58-ca2f7e7a80e9", "source_file": "PMC10399933.json", "annotation_id": "1452195940", "pmid": "37490620", "original_sentence": "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.", "blanked_sentence": "Genotype _____ is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CC"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "852330a6-543a-4e00-be40-3594f08f2556", "source_file": "PMC10399933.json", "annotation_id": "1452195940", "pmid": "37490620", "original_sentence": "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.", "blanked_sentence": "Genotype CC is associated with _____ risk of discontinuation when treated with simvastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c13e02ca-4721-4b5a-bea5-cfdd45542808", "source_file": "PMC10399933.json", "annotation_id": "1452195940", "pmid": "37490620", "original_sentence": "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.", "blanked_sentence": "Genotype CC is associated with increased risk of _____ when treated with simvastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Discontinuation"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b9eb7ce1-2923-4485-9be9-864e23a60ef4", "source_file": "PMC10399933.json", "annotation_id": "1452195940", "pmid": "37490620", "original_sentence": "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.", "blanked_sentence": "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["TT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bb9e43a9-495e-453b-b78b-ff7f14feea7e", "source_file": "PMC10399933.json", "annotation_id": "1452195947", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with _____ as compared to genotype TT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["pravastatin"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3d506685-5868-4103-ba7e-89475690005c", "source_file": "PMC10399933.json", "annotation_id": "1452195947", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.", "blanked_sentence": "Genotypes _____ is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CC + CT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "30ed930d-4ce9-4d6a-ba5c-5f8fcad438dd", "source_file": "PMC10399933.json", "annotation_id": "1452195947", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with _____ risk of discontinuation when treated with pravastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "10523f86-44d8-4970-98fa-44a916927ab1", "source_file": "PMC10399933.json", "annotation_id": "1452195947", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with increased risk of _____ when treated with pravastatin as compared to genotype TT.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Discontinuation"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ef5c4c1c-9ace-4dde-abed-cadd1b5fc0c8", "source_file": "PMC10399933.json", "annotation_id": "1452195947", "pmid": "37490620", "original_sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["TT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cd80cd17-1e45-4075-a492-063baf17c5e1", "source_file": "PMC10786722.json", "annotation_id": "1452352260", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes _____ is associated with decreased activity of DPYD as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT + TT"], "field_category": "Alleles"}], "annotation_type": "var_fa_ann"}
{"question_id": "90d94e7d-0a73-400c-a907-44414eb87697", "source_file": "PMC10786722.json", "annotation_id": "1452352260", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with _____ activity of DPYD as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_fa_ann"}
{"question_id": "a5347109-fc10-45ca-8b27-f4acae048c03", "source_file": "PMC10786722.json", "annotation_id": "1452352260", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with decreased _____ DPYD as compared to genotype CC.", "blanks": [{"blanked_field": "Functional terms", "ground_truth": ["activity of"], "field_category": "Functional terms"}], "annotation_type": "var_fa_ann"}
{"question_id": "df7304d3-23df-4157-81e1-387f2e17468e", "source_file": "PMC10786722.json", "annotation_id": "1452352260", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_fa_ann"}
{"question_id": "82bff08e-32e9-43b7-8374-58fc7b4b78ba", "source_file": "PMC10786722.json", "annotation_id": "1452352325", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes _____ is associated with decreased activity of DPYD as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT + TT"], "field_category": "Alleles"}], "annotation_type": "var_fa_ann"}
{"question_id": "bcb9d03a-afa5-4ba4-9b7c-333529cea176", "source_file": "PMC10786722.json", "annotation_id": "1452352325", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with _____ activity of DPYD as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_fa_ann"}
{"question_id": "3b55bcc3-29c2-4582-ab0d-82a829aece73", "source_file": "PMC10786722.json", "annotation_id": "1452352325", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with decreased _____ DPYD as compared to genotype CC.", "blanks": [{"blanked_field": "Functional terms", "ground_truth": ["activity of"], "field_category": "Functional terms"}], "annotation_type": "var_fa_ann"}
{"question_id": "8248ea82-569c-46b1-906d-024821f01c04", "source_file": "PMC10786722.json", "annotation_id": "1452352325", "pmid": "38216550", "original_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_fa_ann"}
{"question_id": "4ce12e2f-9037-4a68-8dac-fb2f55a82ca5", "source_file": "PMC10786722.json", "annotation_id": "1452352320", "pmid": "38216550", "original_sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.", "blanked_sentence": "Genotypes _____ is associated with decreased activity of DPYD as compared to genotype TT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CC + CT"], "field_category": "Alleles"}], "annotation_type": "var_fa_ann"}
{"question_id": "6dd69ae9-28d6-41b8-820b-d53539f2e17e", "source_file": "PMC10786722.json", "annotation_id": "1452352320", "pmid": "38216550", "original_sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with _____ activity of DPYD as compared to genotype TT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_fa_ann"}
{"question_id": "c4fafeab-c946-4c5c-892e-88affcee5b56", "source_file": "PMC10786722.json", "annotation_id": "1452352320", "pmid": "38216550", "original_sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with decreased _____ DPYD as compared to genotype TT.", "blanks": [{"blanked_field": "Functional terms", "ground_truth": ["activity of"], "field_category": "Functional terms"}], "annotation_type": "var_fa_ann"}
{"question_id": "fccb375d-cb60-4984-889e-f6cf5498931c", "source_file": "PMC10786722.json", "annotation_id": "1452352320", "pmid": "38216550", "original_sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["TT"], "field_category": "Comparison"}], "annotation_type": "var_fa_ann"}
{"question_id": "b405ae58-1598-4fc2-819b-bed34fbda82d", "source_file": "PMC10880264.json", "annotation_id": "1452390346", "pmid": "38377518", "original_sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanked_sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of _____ in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["escitalopram"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "e29e5645-73c4-43e0-8b21-58581ccf1d7e", "source_file": "PMC10880264.json", "annotation_id": "1452390346", "pmid": "38377518", "original_sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanked_sentence": "CYP2C19 intermediate metabolizer is associated with _____ dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "8d61243b-34dd-4262-8ca0-e095261ee9a2", "source_file": "PMC10880264.json", "annotation_id": "1452390346", "pmid": "38377518", "original_sentence": "CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanked_sentence": "CYP2C19 intermediate metabolizer is associated with increased _____ escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose-adjusted trough concentrations of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "afaa1cf5-45d4-4106-9162-6d102d09e33c", "source_file": "PMC10880264.json", "annotation_id": "1452390389", "pmid": "38377518", "original_sentence": "CYP2D6 poor metabolizer is associated with increased likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer.", "blanked_sentence": "CYP2D6 poor metabolizer is associated with increased likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with _____ in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["escitalopram"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "eab106ef-71b9-4ec7-a088-3276821e40a9", "source_file": "PMC10880264.json", "annotation_id": "1452390389", "pmid": "38377518", "original_sentence": "CYP2D6 poor metabolizer is associated with increased likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer.", "blanked_sentence": "CYP2D6 poor metabolizer is associated with _____ likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8b4980fa-7b24-47e6-b033-e2bcdbca1dc3", "source_file": "PMC10880264.json", "annotation_id": "1452390301", "pmid": "38377518", "original_sentence": "CYP2C19 intermediate metabolizer is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanked_sentence": "CYP2C19 intermediate metabolizer is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with _____ in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["escitalopram"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5f82642d-b269-4796-857b-9099c6ed2f6c", "source_file": "PMC10880264.json", "annotation_id": "1452390301", "pmid": "38377518", "original_sentence": "CYP2C19 intermediate metabolizer is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanked_sentence": "CYP2C19 intermediate metabolizer is associated with _____ likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ee83c7d7-1431-41c6-b4bb-a02979858f52", "source_file": "PMC10880264.json", "annotation_id": "1452390352", "pmid": "38377518", "original_sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .", "blanked_sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with _____ in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["escitalopram"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c8a6e20c-7573-4c17-8540-e199dfd195c4", "source_file": "PMC10880264.json", "annotation_id": "1452390352", "pmid": "38377518", "original_sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .", "blanked_sentence": "Genotypes _____ (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT + TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "82a8436a-1521-4c36-8ab7-6418a922a2ac", "source_file": "PMC10880264.json", "annotation_id": "1452390352", "pmid": "38377518", "original_sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .", "blanked_sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with _____ likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "14f28fab-303b-4132-b651-89a966925e72", "source_file": "PMC10880264.json", "annotation_id": "1452390352", "pmid": "38377518", "original_sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .", "blanked_sentence": "Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype _____ (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "be8bd5bd-1d81-49da-b1ac-de09d1288ce7", "source_file": "PMC10946077.json", "annotation_id": "1452426860", "pmid": "38497131", "original_sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with _____ in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["irinotecan"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "746b69a5-db30-4bb6-a6eb-e3c5de0b96ad", "source_file": "PMC10946077.json", "annotation_id": "1452426860", "pmid": "38497131", "original_sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 _____ is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*6 + *28"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "98e197a2-e2e7-4312-89c1-f770496aa8b3", "source_file": "PMC10946077.json", "annotation_id": "1452426860", "pmid": "38497131", "original_sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *6 + *28 is not associated with _____ likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "52ec1392-17b2-4f41-86ce-71fab4859d45", "source_file": "PMC10946077.json", "annotation_id": "1452426860", "pmid": "38497131", "original_sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "377b2ed7-5f49-4464-ba6a-066026d5e6cd", "source_file": "PMC10946077.json", "annotation_id": "1452426882", "pmid": "38497131", "original_sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with _____ in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["irinotecan"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "df2b756b-5cee-4c52-add5-116e63684240", "source_file": "PMC10946077.json", "annotation_id": "1452426882", "pmid": "38497131", "original_sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 _____ is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*28"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "27143925-87ac-4c0d-8d8d-c614456d5fe7", "source_file": "PMC10946077.json", "annotation_id": "1452426882", "pmid": "38497131", "original_sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *28 is not associated with _____ severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9903925f-3fa2-46d4-a642-228d2d1fe33c", "source_file": "PMC10946077.json", "annotation_id": "1452426882", "pmid": "38497131", "original_sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8f498921-8564-475e-8420-477d4019c801", "source_file": "PMC10946077.json", "annotation_id": "1452426961", "pmid": "38497131", "original_sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with _____ in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["irinotecan"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "21f9491f-7911-4b9b-a47d-4eddde0f344d", "source_file": "PMC10946077.json", "annotation_id": "1452426961", "pmid": "38497131", "original_sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 _____ is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*6"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9c3b8ca1-e9f6-41af-ae1f-e31227212c34", "source_file": "PMC10946077.json", "annotation_id": "1452426961", "pmid": "38497131", "original_sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *6 is associated with _____ severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b4b77fa1-0a45-442a-88c4-de0afff8e057", "source_file": "PMC10946077.json", "annotation_id": "1452426961", "pmid": "38497131", "original_sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "blanked_sentence": "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "37b94cfe-aa26-417d-aa83-6426864fcc4d", "source_file": "PMC10993165.json", "annotation_id": "1452437420", "pmid": "38568509", "original_sentence": "HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanked_sentence": "HLA-B _____ is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "19bfdc23-c124-48ff-b106-6dd9cb07875c", "source_file": "PMC10993165.json", "annotation_id": "1452437420", "pmid": "38568509", "original_sentence": "HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanked_sentence": "HLA-B *15:02 is associated with _____ likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "17e3b0b2-d546-4b8d-8f5c-6479379b8126", "source_file": "PMC10993165.json", "annotation_id": "1452438980", "pmid": "38568509", "original_sentence": "HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanked_sentence": "HLA-B _____ is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*13:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2cccef22-2580-4e58-b777-8939f2f5723b", "source_file": "PMC10993165.json", "annotation_id": "1452438980", "pmid": "38568509", "original_sentence": "HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanked_sentence": "HLA-B *13:01 is associated with _____ likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cf3361ee-9d65-4d9f-8521-4bda3534b018", "source_file": "PMC10993165.json", "annotation_id": "1452438980", "pmid": "38568509", "original_sentence": "HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanked_sentence": "HLA-B *13:01 is associated with increased likelihood of _____ when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Severe Cutaneous Adverse Reactions"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "26e6ea29-403d-4c75-8389-250ae27a7b2c", "source_file": "PMC10993165.json", "annotation_id": "1452439000", "pmid": "38568509", "original_sentence": "HLA-B *38:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanked_sentence": "HLA-B _____ is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*38:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "39a3db26-2da3-4467-887c-823e18df5856", "source_file": "PMC10993165.json", "annotation_id": "1452439000", "pmid": "38568509", "original_sentence": "HLA-B *38:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanked_sentence": "HLA-B *38:02 is associated with _____ likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "31d427e0-f0a0-47f7-a8ae-305070c79f5f", "source_file": "PMC11062152.json", "annotation_id": "1452474670", "pmid": "38707740", "original_sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanked_sentence": "UGT1A1 _____ is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*6 + *28"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f69c629c-1b21-4162-b2c7-fd14c3f4da32", "source_file": "PMC11062152.json", "annotation_id": "1452474670", "pmid": "38707740", "original_sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanked_sentence": "UGT1A1 *6 + *28 is not associated with _____ risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4f9f5d52-e710-4c6b-a653-9fe2b407806b", "source_file": "PMC11062152.json", "annotation_id": "1452474670", "pmid": "38707740", "original_sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanked_sentence": "UGT1A1 *6 + *28 is not associated with increased risk of _____ when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Diarrhea"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8990bfea-4788-428f-a3c2-648d30e2a24c", "source_file": "PMC11062152.json", "annotation_id": "1452474670", "pmid": "38707740", "original_sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanked_sentence": "UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b3b124b4-1281-4458-b8eb-79ba6d56c0fc", "source_file": "PMC11062152.json", "annotation_id": "1452474678", "pmid": "38707740", "original_sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanked_sentence": "UGT1A1 _____ is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*6/*6 + *28/*28 + *6/*28"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3953ef73-9c6b-4ef1-9ddb-1df7760bef2f", "source_file": "PMC11062152.json", "annotation_id": "1452474678", "pmid": "38707740", "original_sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanked_sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with _____ risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c495e127-536c-4230-96cc-0663a6699fc0", "source_file": "PMC11062152.json", "annotation_id": "1452474678", "pmid": "38707740", "original_sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "blanked_sentence": "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e2dc339b-6eaa-4a66-9d91-d9d6bffd593e", "source_file": "PMC11430164.json", "annotation_id": "1452626580", "pmid": "39346054", "original_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of _____ as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["ticagrelor"], "field_category": "Drug(s)"}], "annotation_type": "var_fa_ann"}
{"question_id": "4b484efb-3e5a-4edf-a254-f17e20a3d712", "source_file": "PMC11430164.json", "annotation_id": "1452626580", "pmid": "39346054", "original_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 _____ is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31"], "field_category": "Alleles"}], "annotation_type": "var_fa_ann"}
{"question_id": "05a22163-f8cf-4069-a8bb-de4e05a43077", "source_file": "PMC11430164.json", "annotation_id": "1452626580", "pmid": "39346054", "original_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with _____ clearance of ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_fa_ann"}
{"question_id": "e087ee7a-3d64-497d-a91c-9776b4a643c2", "source_file": "PMC11430164.json", "annotation_id": "1452626580", "pmid": "39346054", "original_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased _____ ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Functional terms", "ground_truth": ["clearance of"], "field_category": "Functional terms"}], "annotation_type": "var_fa_ann"}
{"question_id": "f3a7025f-5a6e-4a14-8721-e194f86c786e", "source_file": "PMC11430164.json", "annotation_id": "1452626580", "pmid": "39346054", "original_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 *2 + *3 + *4 + *5 + *9 + _____4 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1"], "field_category": "Comparison"}], "annotation_type": "var_fa_ann"}
{"question_id": "112e98a9-b08a-4945-add9-6d610b64b65c", "source_file": "PMC11430164.json", "annotation_id": "1452626560", "pmid": "39346054", "original_sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of _____ as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["ticagrelor"], "field_category": "Drug(s)"}], "annotation_type": "var_fa_ann"}
{"question_id": "bc803c05-fad9-48fb-8979-504d136bac98", "source_file": "PMC11430164.json", "annotation_id": "1452626560", "pmid": "39346054", "original_sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 _____ is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*11 + *18 + *33"], "field_category": "Alleles"}], "annotation_type": "var_fa_ann"}
{"question_id": "6f5ded72-e0be-4ab4-b809-05ed77a039e3", "source_file": "PMC11430164.json", "annotation_id": "1452626560", "pmid": "39346054", "original_sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 *11 + *18 + *33 is associated with _____ clearance of ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_fa_ann"}
{"question_id": "545da026-8f88-4900-8197-18742d1735ca", "source_file": "PMC11430164.json", "annotation_id": "1452626560", "pmid": "39346054", "original_sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 *11 + *18 + *33 is associated with increased _____ ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Functional terms", "ground_truth": ["clearance of"], "field_category": "Functional terms"}], "annotation_type": "var_fa_ann"}
{"question_id": "520f5e05-df0b-481b-9cb2-573ebae2fddd", "source_file": "PMC11430164.json", "annotation_id": "1452626560", "pmid": "39346054", "original_sentence": "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.", "blanked_sentence": "CYP3A4 _____1 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1"], "field_category": "Comparison"}], "annotation_type": "var_fa_ann"}
{"question_id": "5b0ba6cf-63da-456e-ab34-c46ed412b3e5", "source_file": "PMC11603346.json", "annotation_id": "1452720980", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with _____ in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9e9596cd-7f92-49fa-b263-91b9b4e5ac2a", "source_file": "PMC11603346.json", "annotation_id": "1452720980", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 _____ is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*1/*6 + *6/*6"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7405890f-19b8-433b-b1ed-c4080b5bb3f3", "source_file": "PMC11603346.json", "annotation_id": "1452720980", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with _____ likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f9694e78-91e6-4256-ab4b-aa9d3abd9ce7", "source_file": "PMC11603346.json", "annotation_id": "1452720980", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of _____ when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug-induced liver injury"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7bb860b0-8bf9-4d1b-882c-f53ae3e8df83", "source_file": "PMC11603346.json", "annotation_id": "1452720980", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a56cfdd9-a57b-4b12-9a03-7a594878482d", "source_file": "PMC11603346.json", "annotation_id": "1452721001", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with _____ in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "aeef374b-7316-4eef-9daf-7acbf7d5733f", "source_file": "PMC11603346.json", "annotation_id": "1452721001", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 _____ is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*1/*6 + *6/*6"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4d345347-bfbc-416d-8c33-4fd02c63bb71", "source_file": "PMC11603346.json", "annotation_id": "1452721001", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with _____ likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "74779081-2334-47c9-a2c6-400b2ed8afcd", "source_file": "PMC11603346.json", "annotation_id": "1452721001", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of _____ when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug-induced liver injury"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "834df9aa-64bb-4c5d-aea0-e1b2d4d920e7", "source_file": "PMC11603346.json", "annotation_id": "1452721001", "pmid": "39604537", "original_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c32a53f8-74a4-4dd9-a2b7-8c5c8aa17eb2", "source_file": "PMC11971672.json", "annotation_id": "1453096120", "pmid": "40184070", "original_sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .", "blanked_sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with _____ in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["clopidogrel"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "221123e9-7c87-47a0-994d-6493f805439d", "source_file": "PMC11971672.json", "annotation_id": "1453096120", "pmid": "40184070", "original_sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .", "blanked_sentence": "CYP2C19 _____ (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5ae986b2-a45c-44fb-abe3-dcc4bb912006", "source_file": "PMC11971672.json", "annotation_id": "1453096120", "pmid": "40184070", "original_sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .", "blanked_sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with _____ likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b71731f3-8f9a-4dff-a30f-6158675651f8", "source_file": "PMC11971672.json", "annotation_id": "1453096120", "pmid": "40184070", "original_sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .", "blanked_sentence": "CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 _____ (assigned as normal metabolizer phenotype) .", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1 + *1/*17 + *17/*17"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3e680372-b2c2-47bf-ba4f-ec51ca3d5d6e", "source_file": "PMC12035587.json", "annotation_id": "1453076180", "pmid": "40099566", "original_sentence": "NUDT15 *3/*3 is associated with increased severity of Myelosuppression, Toxic liver disease and Alopecia when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute.", "blanked_sentence": "NUDT15 *3/*3 is associated with increased severity of Myelosuppression, Toxic liver disease and Alopecia when treated with _____ in women with Leukemia, Promyelocytic, Acute.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["mercaptopurine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "dce31914-7b29-4c7a-913a-ca8f8893d2e3", "source_file": "PMC12035587.json", "annotation_id": "1453076180", "pmid": "40099566", "original_sentence": "NUDT15 *3/*3 is associated with increased severity of Myelosuppression, Toxic liver disease and Alopecia when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute.", "blanked_sentence": "NUDT15 _____ is associated with increased severity of Myelosuppression, Toxic liver disease and Alopecia when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*3/*3"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bd8236a4-df4c-4744-8132-b7c950ce4ba5", "source_file": "PMC12035587.json", "annotation_id": "1453076180", "pmid": "40099566", "original_sentence": "NUDT15 *3/*3 is associated with increased severity of Myelosuppression, Toxic liver disease and Alopecia when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute.", "blanked_sentence": "NUDT15 *3/*3 is associated with _____ severity of Myelosuppression, Toxic liver disease and Alopecia when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4dd30406-8a21-46f6-91df-fb2b00d6ff6e", "source_file": "PMC12036300.json", "annotation_id": "1454052100", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with _____ as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["clopidogrel"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bd17f526-da8f-4529-9cbd-e9da3d451286", "source_file": "PMC12036300.json", "annotation_id": "1454052100", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 _____ is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*1/*2 + *2/*2 + *2/*17"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "001540da-dbe3-4e63-88af-8bb6a3594912", "source_file": "PMC12036300.json", "annotation_id": "1454052100", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with _____ likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "99071006-18a2-4c4e-b37c-9e45126d295a", "source_file": "PMC12036300.json", "annotation_id": "1454052100", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of _____ when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Major Adverse Cardiac Events (MACE)"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f0659910-d0a8-4811-a64a-b20a9bec1dc3", "source_file": "PMC12036300.json", "annotation_id": "1454052100", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "54b8cb6c-9bde-4ef1-82e6-47ad1d50b34c", "source_file": "PMC12036300.json", "annotation_id": "1454052160", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with _____ as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["clopidogrel"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2aba4e12-bf0b-4a3c-9278-46496939ff1f", "source_file": "PMC12036300.json", "annotation_id": "1454052160", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 _____ is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*1/*17 + *17/*17 + *2/*17"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8d95d1c0-3720-4098-a922-e75482e89862", "source_file": "PMC12036300.json", "annotation_id": "1454052160", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with _____ likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cc227ccd-dc4f-4a7f-a8fe-2c140b028301", "source_file": "PMC12036300.json", "annotation_id": "1454052160", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of _____ when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Hemorrhage"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a3920311-e2f7-4f37-8b66-627f84f4c8a1", "source_file": "PMC12036300.json", "annotation_id": "1454052160", "pmid": "40295977", "original_sentence": "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanked_sentence": "CYP2C19 _____7 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "52fd0fd3-402d-48e1-8594-880a7b86b698", "source_file": "PMC12038368.json", "annotation_id": "1454052260", "pmid": "40297930", "original_sentence": "Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with increased concentrations of _____ in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["simvastatin acid"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "517fe440-3317-42e0-b4ca-57559c3856da", "source_file": "PMC12038368.json", "annotation_id": "1454052260", "pmid": "40297930", "original_sentence": "Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanked_sentence": "Genotypes _____ is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CC + CT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "f971555b-9634-4058-a430-f5369b58e96b", "source_file": "PMC12038368.json", "annotation_id": "1454052260", "pmid": "40297930", "original_sentence": "Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with _____ concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "f1df6f2f-1eaf-4285-bf64-81589c6c0362", "source_file": "PMC12038368.json", "annotation_id": "1454052260", "pmid": "40297930", "original_sentence": "Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with increased _____ simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["concentrations of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "85b45897-666e-4e1d-af5d-0c002825cd9f", "source_file": "PMC12038368.json", "annotation_id": "1454052260", "pmid": "40297930", "original_sentence": "Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["TT"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "93775202-eb7d-45cb-a0f1-ca4dba33940c", "source_file": "PMC12038368.json", "annotation_id": "1454052282", "pmid": "40297930", "original_sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG is associated with increased concentrations of _____ in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["simvastatin acid"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "b127f32b-aa46-4461-8936-5e6af0e81ad2", "source_file": "PMC12038368.json", "annotation_id": "1454052282", "pmid": "40297930", "original_sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanked_sentence": "Genotypes _____ is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AG + GG"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "1e990bcb-ae1d-45b3-bf3e-04c1130c48a7", "source_file": "PMC12038368.json", "annotation_id": "1454052282", "pmid": "40297930", "original_sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG is associated with _____ concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "fc58c069-bf4a-476d-bc83-597fdd43ece1", "source_file": "PMC12038368.json", "annotation_id": "1454052282", "pmid": "40297930", "original_sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG is associated with increased _____ simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["concentrations of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "62b752d5-e54b-4e75-af80-549b3f0e8f7d", "source_file": "PMC12038368.json", "annotation_id": "1454052282", "pmid": "40297930", "original_sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "7f38e3df-dd60-4084-a2f9-98a389b60b57", "source_file": "PMC12319246.json", "annotation_id": "1454211330", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with _____ in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ae2bd200-d58b-4538-bc9d-0ea34b3c3016", "source_file": "PMC12319246.json", "annotation_id": "1454211330", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype _____ is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e4b809c8-6fa3-4128-a1b4-5843c0a0b575", "source_file": "PMC12319246.json", "annotation_id": "1454211330", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with _____ likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "af8d9d5d-e6d5-46f2-b0e9-2bc276454458", "source_file": "PMC12319246.json", "annotation_id": "1454211330", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC + CT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7d652eae-d3f8-4373-a643-a9ba1bccd3d5", "source_file": "PMC12319246.json", "annotation_id": "1454211347", "pmid": "40761554", "original_sentence": "Genotype GT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype GT is associated with decreased likelihood of Transplant rejection when treated with _____ in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "83f80b03-c0de-49e7-a122-4c9f7e25d51f", "source_file": "PMC12319246.json", "annotation_id": "1454211347", "pmid": "40761554", "original_sentence": "Genotype GT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype _____ is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["GT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ea5489a1-65ed-4126-8e2f-f0be06fc114f", "source_file": "PMC12319246.json", "annotation_id": "1454211347", "pmid": "40761554", "original_sentence": "Genotype GT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype GT is associated with _____ likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "48b65641-de57-4141-b5d0-cc89bdfd73dc", "source_file": "PMC12319246.json", "annotation_id": "1454211400", "pmid": "40761554", "original_sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with _____ in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "908df950-72b4-473f-9061-a1f9623c7e45", "source_file": "PMC12319246.json", "annotation_id": "1454211400", "pmid": "40761554", "original_sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotypes _____ is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AA + AG"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "69ff1d37-4a88-4313-a606-93ddff4004c2", "source_file": "PMC12319246.json", "annotation_id": "1454211400", "pmid": "40761554", "original_sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotypes AA + AG is associated with _____ likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a8f02ad4-75bf-4700-8b79-045c1f60b6a6", "source_file": "PMC12319246.json", "annotation_id": "1454211400", "pmid": "40761554", "original_sentence": "Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotypes AA + AG is associated with decreased likelihood of _____ when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Nephrotoxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "166c76c8-a52b-4c35-9db2-b81ad53c1fbf", "source_file": "PMC12319246.json", "annotation_id": "1454211260", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased risk of Death when treated with _____ in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5fa5a594-7345-41c9-86d7-a13060ee7fb6", "source_file": "PMC12319246.json", "annotation_id": "1454211260", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype _____ is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4fcb9ca2-f253-4e72-9a5d-bde547973211", "source_file": "PMC12319246.json", "annotation_id": "1454211260", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with _____ risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "47dc9e23-f645-49e1-9726-9942d660d79b", "source_file": "PMC12319246.json", "annotation_id": "1454211260", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC + CT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b411916d-46a8-4db5-87d9-b2f86ab598ce", "source_file": "PMC12319246.json", "annotation_id": "1454211271", "pmid": "40761554", "original_sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with _____ in people with Kidney Transplantation as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8cff44bf-4bac-40a9-9761-8452f62b70b9", "source_file": "PMC12319246.json", "annotation_id": "1454211271", "pmid": "40761554", "original_sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.", "blanked_sentence": "Genotype _____ is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["GG"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "231a3102-cd79-4e6b-b31d-8e60f678ba54", "source_file": "PMC12319246.json", "annotation_id": "1454211271", "pmid": "40761554", "original_sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with _____ likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "571cb9e7-5872-48c8-86d9-4aefb959498c", "source_file": "PMC12319246.json", "annotation_id": "1454211271", "pmid": "40761554", "original_sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA + AG"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "16f095ff-82d6-4d4b-ac88-5a46cbbf2308", "source_file": "PMC12319246.json", "annotation_id": "1454211280", "pmid": "40761554", "original_sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.", "blanked_sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with _____ in people with Kidney Transplantation as compared to genotype CT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1ac620a1-ad0d-40fa-8ce0-65b8f85a72c4", "source_file": "PMC12319246.json", "annotation_id": "1454211280", "pmid": "40761554", "original_sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.", "blanked_sentence": "Genotype _____ is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CC"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "67062908-74a1-4763-8a8d-e55517c7336a", "source_file": "PMC12319246.json", "annotation_id": "1454211280", "pmid": "40761554", "original_sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.", "blanked_sentence": "Genotype CC is associated with _____ likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2c977fc8-43fa-43c2-8ea5-2a1703706bd0", "source_file": "PMC12319246.json", "annotation_id": "1454211280", "pmid": "40761554", "original_sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT.", "blanked_sentence": "Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c20adead-6cd4-498a-8295-c8738dcdd2ec", "source_file": "PMC12319246.json", "annotation_id": "1454211340", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with _____ in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ff2d0653-4748-4f5e-9f4e-40c26a5d9a93", "source_file": "PMC12319246.json", "annotation_id": "1454211340", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype _____ is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a21838d6-8895-45d3-90f0-5cc71b6974ee", "source_file": "PMC12319246.json", "annotation_id": "1454211340", "pmid": "40761554", "original_sentence": "Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype TT is associated with _____ likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f3d066d9-f37f-4581-936b-da275d9f4024", "source_file": "PMC12319246.json", "annotation_id": "1454211323", "pmid": "40761554", "original_sentence": "Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with _____ in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tacrolimus"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "af5ad501-e6fc-4444-a5a4-ec5236d5b1ad", "source_file": "PMC12319246.json", "annotation_id": "1454211323", "pmid": "40761554", "original_sentence": "Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype _____ is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AA"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e5194a89-54b8-45a1-af9b-f8ffa516a8ad", "source_file": "PMC12319246.json", "annotation_id": "1454211323", "pmid": "40761554", "original_sentence": "Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype AA is associated with _____ likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "26746bd1-73a1-45c0-ba75-b1f402ba685e", "source_file": "PMC12319246.json", "annotation_id": "1454211323", "pmid": "40761554", "original_sentence": "Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.", "blanked_sentence": "Genotype AA is associated with increased likelihood of _____ when treated with tacrolimus in people with Kidney Transplantation.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Nephrotoxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "eb7b72da-b12c-46a0-946e-2668932127e5", "source_file": "PMC12331468.json", "annotation_id": "1454223600", "pmid": "40786508", "original_sentence": "Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.", "blanked_sentence": "Genotypes _____ is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AG + GG"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c14f4923-40ed-4e6c-a735-e4fcff42dc80", "source_file": "PMC12331468.json", "annotation_id": "1454223600", "pmid": "40786508", "original_sentence": "Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG is associated with _____ likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ab1ddfe1-e2fe-4a7d-aa70-2d4ddeda3957", "source_file": "PMC12331468.json", "annotation_id": "1454223600", "pmid": "40786508", "original_sentence": "Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG is associated with increased likelihood of _____ when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Peripheral Nervous System Diseases"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c132d3d2-0e62-4e1b-8ef4-4194311cfa93", "source_file": "PMC12331468.json", "annotation_id": "1454223600", "pmid": "40786508", "original_sentence": "Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "68a3ee84-7bcf-427a-bb0e-5e611a016c11", "source_file": "PMC12331468.json", "annotation_id": "1454223640", "pmid": "40786508", "original_sentence": "Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanked_sentence": "Genotype _____ is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["GG"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2728ecfa-d373-47dd-8019-fe84f303722a", "source_file": "PMC12331468.json", "annotation_id": "1454223640", "pmid": "40786508", "original_sentence": "Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with _____ likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0f7f55c2-779f-4d46-8336-5098b859ef6c", "source_file": "PMC12331468.json", "annotation_id": "1454223640", "pmid": "40786508", "original_sentence": "Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA + AG"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1f6c3dba-4924-4410-bbe5-dae5c9ed9198", "source_file": "PMC12331468.json", "annotation_id": "1454223652", "pmid": "40786508", "original_sentence": "Genotypes TTA/TTA + TTA/TTAAAGTTA is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanked_sentence": "Genotypes _____ is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TTA/TTA + TTA/TTAAAGTTA"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "681090df-f3f9-45a1-a4c4-f89fb4a33b3d", "source_file": "PMC12331468.json", "annotation_id": "1454223652", "pmid": "40786508", "original_sentence": "Genotypes TTA/TTA + TTA/TTAAAGTTA is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanked_sentence": "Genotypes TTA/TTA + TTA/TTAAAGTTA is associated with _____ likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "49be64b1-2349-46c8-84ed-5d965996f03d", "source_file": "PMC12331468.json", "annotation_id": "1454223625", "pmid": "40786508", "original_sentence": "Genotype (GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3 is associated with increased likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanked_sentence": "Genotype _____ is associated with increased likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "653c7bb4-dd8f-4733-b9d2-c673a323bb46", "source_file": "PMC12331468.json", "annotation_id": "1454223625", "pmid": "40786508", "original_sentence": "Genotype (GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3 is associated with increased likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanked_sentence": "Genotype (GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3 is associated with _____ likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8947f670-3f2a-4fc1-ada2-e7b283c1ed25", "source_file": "PMC12331468.json", "annotation_id": "1454223701", "pmid": "40786508", "original_sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanked_sentence": "Genotype _____ is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["GG"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "6b3d41ce-5c73-405d-8160-bcd8f1c8b6e3", "source_file": "PMC12331468.json", "annotation_id": "1454223701", "pmid": "40786508", "original_sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with _____ likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a031e8f0-5134-4d8b-ae7a-405854eca22a", "source_file": "PMC12331468.json", "annotation_id": "1454223701", "pmid": "40786508", "original_sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with increased likelihood of _____ when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Mucositis"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "88707332-c154-4f10-ba2b-0313910fec77", "source_file": "PMC12331468.json", "annotation_id": "1454223701", "pmid": "40786508", "original_sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "blanked_sentence": "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA + AG"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "29a79e8f-ccca-4787-91fc-474715bc7633", "source_file": "PMC2859392.json", "annotation_id": "1448993666", "pmid": "20338069", "original_sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype TT is not associated with response to _____ in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "3a8383c1-6cf3-4f3f-9d03-93be602b9775", "source_file": "PMC2859392.json", "annotation_id": "1448993666", "pmid": "20338069", "original_sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype _____ is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "b384a40d-0a37-441a-a7a0-77a0d25b061e", "source_file": "PMC2859392.json", "annotation_id": "1448993666", "pmid": "20338069", "original_sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype TT is not associated with _____ efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["response to"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "3f26b1b7-df3a-4b79-ae27-f0d67c44f906", "source_file": "PMC2859392.json", "annotation_id": "1448993666", "pmid": "20338069", "original_sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["GG + GT"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "37833e1f-aa08-4c04-837d-f46bf6ae32ba", "source_file": "PMC2859392.json", "annotation_id": "1184988061", "pmid": "20338069", "original_sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype TT is associated with decreased metabolism of _____ in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "c288bcf9-09f2-423b-9e0d-0bcc58de7ff8", "source_file": "PMC2859392.json", "annotation_id": "1184988061", "pmid": "20338069", "original_sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype _____ is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "6f5fb490-1b61-4139-944e-95b125a6f2fc", "source_file": "PMC2859392.json", "annotation_id": "1184988061", "pmid": "20338069", "original_sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype TT is associated with _____ metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "54b1dc99-d4a7-4e02-8949-5049d37143b5", "source_file": "PMC2859392.json", "annotation_id": "1184988061", "pmid": "20338069", "original_sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype TT is associated with decreased _____ efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["metabolism of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "65caa638-86fc-4307-873c-8806d84a14db", "source_file": "PMC2859392.json", "annotation_id": "1184988061", "pmid": "20338069", "original_sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "blanked_sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["GG + GT"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "b9bc97b0-3a0d-49bc-9064-3fca8991f787", "source_file": "PMC3113609.json", "annotation_id": "1184466922", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3d9473e7-c22d-4b90-9704-7babe6bbd7ab", "source_file": "PMC3113609.json", "annotation_id": "1184466922", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.", "blanked_sentence": "HLA-A _____ is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*31:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0d37e79f-a1b4-4bdf-854e-cc1bf2e30949", "source_file": "PMC3113609.json", "annotation_id": "1184466922", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with _____ risk of severe cutaneous adverse reactions when treated with carbamazepine.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9ea2d3d2-6418-4bd3-a916-aaffc531ade9", "source_file": "PMC3113609.json", "annotation_id": "1184466922", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of _____ when treated with carbamazepine.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Severe Cutaneous Adverse Reactions"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cd8fd478-abe8-4968-8ae4-069c4eb5b460", "source_file": "PMC3113609.json", "annotation_id": "1184466916", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5eda8d94-075e-4886-bec7-5e0ac4c80c2a", "source_file": "PMC3113609.json", "annotation_id": "1184466916", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.", "blanked_sentence": "HLA-A _____ is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*31:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f3a820c3-e3e3-4f1c-9975-152ea2cb336f", "source_file": "PMC3113609.json", "annotation_id": "1184466916", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with _____ risk of Maculopapular Exanthema when treated with carbamazepine.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1586065f-f8c8-4cf0-a200-dd0a803470e7", "source_file": "PMC3113609.json", "annotation_id": "1184466916", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of _____ when treated with carbamazepine.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Maculopapular Exanthema"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "13a0e3bb-3a4e-4915-bc5b-832fc5d2c3aa", "source_file": "PMC3113609.json", "annotation_id": "1184466909", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cae9a8ac-fb98-48a5-bd0c-4f86e937b0dd", "source_file": "PMC3113609.json", "annotation_id": "1184466909", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.", "blanked_sentence": "HLA-A _____ is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*31:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "328e1560-731f-441b-b7cb-a232cf183262", "source_file": "PMC3113609.json", "annotation_id": "1184466909", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with _____ risk of Drug Hypersensitivity when treated with carbamazepine.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "59e0928d-be9f-4825-94bc-e4e9976dafac", "source_file": "PMC3113609.json", "annotation_id": "1184466909", "pmid": "21428769", "original_sentence": "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of _____ when treated with carbamazepine.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Hypersensitivity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "17341494-e8e2-4915-8dbd-b08ed643d761", "source_file": "PMC3387531.json", "annotation_id": "1185002091", "pmid": "21505298", "original_sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e32bf3f6-eaa5-4be7-942d-d4379582a3a1", "source_file": "PMC3387531.json", "annotation_id": "1185002091", "pmid": "21505298", "original_sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*35:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ec75ac55-b2d2-4aae-9490-a4abe3458ddb", "source_file": "PMC3387531.json", "annotation_id": "1185002091", "pmid": "21505298", "original_sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *35:01 is associated with _____ risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "57f4369c-bd05-4e82-89c5-3a630cbe76c0", "source_file": "PMC3387531.json", "annotation_id": "1185002091", "pmid": "21505298", "original_sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *35:01 is associated with increased risk of _____ when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Toxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e9985ae2-ec60-4c5c-be36-965936773f54", "source_file": "PMC3387531.json", "annotation_id": "1185002083", "pmid": "21505298", "original_sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "29775d9a-7aa2-4ff3-a253-d1885c4d1a1f", "source_file": "PMC3387531.json", "annotation_id": "1185002083", "pmid": "21505298", "original_sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 _____ is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*01:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a77f7ea6-b5b5-4e1e-b920-ec29fd2c5e17", "source_file": "PMC3387531.json", "annotation_id": "1185002083", "pmid": "21505298", "original_sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *01:01 is associated with _____ risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "28ae02db-2f19-4696-b198-4077c5d1c1a8", "source_file": "PMC3387531.json", "annotation_id": "1185002083", "pmid": "21505298", "original_sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *01:01 is associated with increased risk of _____ when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Toxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "da19398d-f7fd-498c-a45b-ca804a6944dc", "source_file": "PMC3387531.json", "annotation_id": "1185002071", "pmid": "21505298", "original_sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8345e632-284f-419b-be3f-406744bcd0d6", "source_file": "PMC3387531.json", "annotation_id": "1185002071", "pmid": "21505298", "original_sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*04:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "04df3f05-6648-46f3-ab67-bf8486c1d2d5", "source_file": "PMC3387531.json", "annotation_id": "1185002071", "pmid": "21505298", "original_sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *04:01 is associated with _____ risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "96500827-ae16-40dd-b13d-95ce31b749ec", "source_file": "PMC3387531.json", "annotation_id": "1185002071", "pmid": "21505298", "original_sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *04:01 is associated with increased risk of _____ when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Toxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "80eb8fe4-4776-49af-b6b4-fc5cf1edc32c", "source_file": "PMC3387531.json", "annotation_id": "1185002120", "pmid": "21505298", "original_sentence": "Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele T is associated with increased risk of Drug Toxicity when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8b5a940c-e9bd-4e62-bb2c-a60517ad40b9", "source_file": "PMC3387531.json", "annotation_id": "1185002120", "pmid": "21505298", "original_sentence": "Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele _____ is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["T"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a9ec9379-a90d-4a9a-a02b-6b7e37163b87", "source_file": "PMC3387531.json", "annotation_id": "1185002120", "pmid": "21505298", "original_sentence": "Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele T is associated with _____ risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "11cdf184-a5a3-473a-91fe-baebfee38d3c", "source_file": "PMC3387531.json", "annotation_id": "1185002120", "pmid": "21505298", "original_sentence": "Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele T is associated with increased risk of _____ when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Toxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5667ae0d-2622-4a08-91ea-c4410d775e97", "source_file": "PMC3387531.json", "annotation_id": "1185002099", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2ece6880-9ed3-4702-86ad-6a9c8231fc6d", "source_file": "PMC3387531.json", "annotation_id": "1185002099", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele _____ is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["C"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cf6be1f2-790a-49db-945a-dd3c063ac013", "source_file": "PMC3387531.json", "annotation_id": "1185002099", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele C is associated with _____ risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ff9f7614-f4bf-4df9-9cae-a96c460fb8e8", "source_file": "PMC3387531.json", "annotation_id": "1185002099", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele C is associated with increased risk of _____ when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Toxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "33e5d14e-85bc-450f-8c03-3f0ca5e10bb0", "source_file": "PMC3387531.json", "annotation_id": "1185002114", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5dfa9997-2a34-46ec-9177-0f2482dab042", "source_file": "PMC3387531.json", "annotation_id": "1185002114", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele _____ is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["C"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3c502275-27d8-41a4-8ab8-0b59f3f7ad39", "source_file": "PMC3387531.json", "annotation_id": "1185002114", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele C is associated with _____ risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c1720a31-b88f-498a-808f-7717931a004a", "source_file": "PMC3387531.json", "annotation_id": "1185002114", "pmid": "21505298", "original_sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "Allele C is associated with increased risk of _____ when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Toxicity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "36e80e04-c982-45f0-a77f-95b71f06ea6f", "source_file": "PMC3548984.json", "annotation_id": "1444933926", "pmid": "23213055", "original_sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with _____ in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tamoxifen"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7de82835-4d96-4e38-b1c7-839119503cc0", "source_file": "PMC3548984.json", "annotation_id": "1444933926", "pmid": "23213055", "original_sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 _____ are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*3/*3 + *4/*4"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3bcbc44b-92b3-493c-9145-27149dd8e4ba", "source_file": "PMC3548984.json", "annotation_id": "1444933926", "pmid": "23213055", "original_sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *3/*3 + *4/*4 are associated with _____ likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4d8213a2-9acf-4003-8dd1-514031186889", "source_file": "PMC3548984.json", "annotation_id": "1444933926", "pmid": "23213055", "original_sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5b8ccddc-37dd-46b8-a676-c30433c9b414", "source_file": "PMC3548984.json", "annotation_id": "1444933959", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with _____ in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tamoxifen"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a2921549-5436-43c0-b7bb-3d3ea4bdcb53", "source_file": "PMC3548984.json", "annotation_id": "1444933959", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 _____ are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*1/*3 + *1/*4 + *1/*6"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "d913db54-4c63-4f03-99c9-1aa5856d3c67", "source_file": "PMC3548984.json", "annotation_id": "1444933959", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with _____ likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "95c0ee58-5fd6-47eb-b645-b1b13fde6068", "source_file": "PMC3548984.json", "annotation_id": "1444933959", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "10d19dae-6611-4fb9-93b3-400a9d13dcfc", "source_file": "PMC3548984.json", "annotation_id": "1444933987", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with _____ in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["tamoxifen"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7c5bb27c-3cc5-40a1-b6fc-08ff9561580f", "source_file": "PMC3548984.json", "annotation_id": "1444933987", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 _____ are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*1/*10 + *1/*41 + *10/*10 + *41/*41"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9dc54690-3b57-46a7-9041-e9d4859bab47", "source_file": "PMC3548984.json", "annotation_id": "1444933987", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with _____ likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4504f9d5-93a6-4dd0-9e3a-d2698ff106e9", "source_file": "PMC3548984.json", "annotation_id": "1444933987", "pmid": "23213055", "original_sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanked_sentence": "CYP2D6 _____0 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2c8f9431-2a58-46e1-96f5-e14fc13c1e08", "source_file": "PMC3584248.json", "annotation_id": "1444930388", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of _____ in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["endoxifen"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "19109a7b-758b-4804-8429-d0d1108a6c19", "source_file": "PMC3584248.json", "annotation_id": "1444930388", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 _____ are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "c02054cb-07be-4d3b-9641-52b661aa5b69", "source_file": "PMC3584248.json", "annotation_id": "1444930388", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with _____ concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "5daa6bb8-61ee-4fc6-8551-42fc0d95f476", "source_file": "PMC3584248.json", "annotation_id": "1444930388", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased _____ endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["concentrations of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "d5f5e532-ed5f-45c9-a017-a559fadeb40a", "source_file": "PMC3584248.json", "annotation_id": "1444930388", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1 + *1/*2 + *2/*2"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "45e3aa7e-1986-4759-a395-520d521dd001", "source_file": "PMC3584248.json", "annotation_id": "1444930474", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 _____ are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "b3fec65c-a39c-4c6a-b349-77c60336a467", "source_file": "PMC3584248.json", "annotation_id": "1444930474", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with _____ concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "d6f3e4f6-b05f-4bad-b796-3faea716ce77", "source_file": "PMC3584248.json", "annotation_id": "1444930474", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased _____ 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["concentrations of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "b6d80b48-41d2-4025-9fee-e6c5756f9702", "source_file": "PMC3584248.json", "annotation_id": "1444930474", "pmid": "23476897", "original_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "blanked_sentence": "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1 + *1/*2 + *2/*2"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "48055650-9a66-4409-a4a7-c390818f8899", "source_file": "PMC3839910.json", "annotation_id": "994166507", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with _____ in children.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "fed9eefd-e677-4dfe-a402-aa65b664049b", "source_file": "PMC3839910.json", "annotation_id": "994166507", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-B _____ is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9b491beb-e28b-4455-b89d-8aae0cb7e0ee", "source_file": "PMC3839910.json", "annotation_id": "994166507", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is associated with _____ risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2bc58e37-17a8-4f12-836d-cd7b2ca3ded9", "source_file": "PMC3839910.json", "annotation_id": "994166507", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is associated with increased risk of _____ when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Stevens-Johnson Syndrome"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a880a93b-e0b2-4ce8-b2b3-a1d31d4b7ad5", "source_file": "PMC3839910.json", "annotation_id": "994531642", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with _____ in children.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "db01fb43-90e2-46b8-a7e2-5795966d44e0", "source_file": "PMC3839910.json", "annotation_id": "994531642", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-B _____ is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "94dcfca2-86d8-48e6-a69e-c5c23b5d82b9", "source_file": "PMC3839910.json", "annotation_id": "994531642", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is not associated with _____ risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4315b006-653c-4be8-a90f-20f1c041092b", "source_file": "PMC3839910.json", "annotation_id": "994531642", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is not associated with increased risk of _____ when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Maculopapular Exanthema"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e2f97a3f-abc0-46d8-820a-a7e038cb1aa2", "source_file": "PMC3839910.json", "annotation_id": "993944301", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with _____ in children.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "db01b7a0-9b91-4d5b-a85b-316106a25dc7", "source_file": "PMC3839910.json", "annotation_id": "993944301", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A _____ is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*31:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f9a44fa6-2ca5-4db2-97a0-01d66594b547", "source_file": "PMC3839910.json", "annotation_id": "993944301", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is not associated with _____ risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e0a7e725-908d-4d14-971e-13871543e495", "source_file": "PMC3839910.json", "annotation_id": "993944301", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is not associated with increased risk of _____ when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Stevens-Johnson Syndrome"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bd552f65-2b15-436a-b411-c7d7518460d4", "source_file": "PMC3839910.json", "annotation_id": "993813998", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with _____ in children.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a384e0a5-fdf8-4241-a648-fe3eb6c0d229", "source_file": "PMC3839910.json", "annotation_id": "993813998", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-A _____ is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*31:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1bb6ce40-4b1b-4890-9d6c-6714061acd9e", "source_file": "PMC3839910.json", "annotation_id": "993813998", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is associated with _____ risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5fcf43fc-ed8f-4a52-8bab-ca1b4fe73357", "source_file": "PMC3839910.json", "annotation_id": "993813998", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of _____ when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Maculopapular Exanthema"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f35a44a4-16f2-4b37-880b-69fc0674ec91", "source_file": "PMC3839910.json", "annotation_id": "992282434", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of _____-induced hypersensitivity syndrome when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "58e843b9-ab70-410e-8c1e-7da84999cbf8", "source_file": "PMC3839910.json", "annotation_id": "992282434", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A _____ is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*31:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "01e549c4-4529-46be-98ee-e40d08fcdc73", "source_file": "PMC3839910.json", "annotation_id": "992282434", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is associated with _____ risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3257e03e-3885-48cf-9444-f62bcab11c69", "source_file": "PMC3839910.json", "annotation_id": "992282434", "pmid": "23588310", "original_sentence": "HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.", "blanked_sentence": "HLA-A *31:01 is associated with increased risk of _____ when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Carbamazepine-induced hypersensitivity syndrome"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "6942e67a-ec0a-4dde-9830-1fe4ab597bd2", "source_file": "PMC3839910.json", "annotation_id": "994398056", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is not associated with increased risk of _____-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["carbamazepine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "40e7b959-f47d-4558-a9b2-b6c607f2fe7b", "source_file": "PMC3839910.json", "annotation_id": "994398056", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.", "blanked_sentence": "HLA-B _____ is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8f34d09a-8360-480d-b7ea-b99a0fa1801f", "source_file": "PMC3839910.json", "annotation_id": "994398056", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is not associated with _____ risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "055df7fd-0d8c-4e2b-ba9f-e920c64f9874", "source_file": "PMC3839910.json", "annotation_id": "994398056", "pmid": "23588310", "original_sentence": "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.", "blanked_sentence": "HLA-B *15:02 is not associated with increased risk of _____ when treated with carbamazepine in children.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Carbamazepine-induced hypersensitivity syndrome (HSS)"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "80c731fa-74c2-4ba3-8bc6-acbb63a086a8", "source_file": "PMC384715.json", "annotation_id": "1444876870", "pmid": "15024131", "original_sentence": "HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.", "blanked_sentence": "HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["abacavir"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a3c18123-d58e-4d86-a38e-c8961faddd70", "source_file": "PMC384715.json", "annotation_id": "1444876870", "pmid": "15024131", "original_sentence": "HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*57:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "55298af2-f541-45c1-8652-f8b3194e0a68", "source_file": "PMC384715.json", "annotation_id": "1444876870", "pmid": "15024131", "original_sentence": "HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.", "blanked_sentence": "HLA-B *57:01 is associated with _____ risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "444e19fa-15bc-4986-935e-1b1372b8ac81", "source_file": "PMC384715.json", "annotation_id": "1444876870", "pmid": "15024131", "original_sentence": "HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.", "blanked_sentence": "HLA-B *57:01 is associated with increased risk of _____ when treated with abacavir in people with HIV Infections.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Drug Hypersensitivity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "80b4fd83-4e50-405b-a588-9a01cbd50e6f", "source_file": "PMC4706412.json", "annotation_id": "1447682700", "pmid": "26745506", "original_sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.", "blanked_sentence": "CYP4F2 *3 is associated with increased dose of _____ as compared to CYP4F2 *1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "756b23bb-1d22-4c28-a2fb-b9c0e5a16442", "source_file": "PMC4706412.json", "annotation_id": "1447682700", "pmid": "26745506", "original_sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.", "blanked_sentence": "CYP4F2 _____ is associated with increased dose of warfarin as compared to CYP4F2 *1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*3"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "f16f5c55-4c45-4792-bf83-0d309b0bb6ae", "source_file": "PMC4706412.json", "annotation_id": "1447682700", "pmid": "26745506", "original_sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.", "blanked_sentence": "CYP4F2 *3 is associated with _____ dose of warfarin as compared to CYP4F2 *1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "ffc3b3d4-c9bc-4b37-8923-568f3db61b42", "source_file": "PMC4706412.json", "annotation_id": "1447682700", "pmid": "26745506", "original_sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.", "blanked_sentence": "CYP4F2 *3 is associated with increased _____ warfarin as compared to CYP4F2 *1.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "9f4377ff-796d-452a-adbf-289cba70161f", "source_file": "PMC4706412.json", "annotation_id": "1447682700", "pmid": "26745506", "original_sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.", "blanked_sentence": "CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "3ad1be74-bb60-40a1-a152-28a6dea6760c", "source_file": "PMC4706412.json", "annotation_id": "1447682605", "pmid": "26745506", "original_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.", "blanked_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of _____ as compared to CYP2C9 *1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "c1ec7391-6af4-463c-b434-758bfb17a657", "source_file": "PMC4706412.json", "annotation_id": "1447682605", "pmid": "26745506", "original_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.", "blanked_sentence": "CYP2C9 _____ are associated with decreased dose of warfarin as compared to CYP2C9 *1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*2 + *3 + *8"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "0668287f-b405-4943-884e-a2914edc639f", "source_file": "PMC4706412.json", "annotation_id": "1447682605", "pmid": "26745506", "original_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.", "blanked_sentence": "CYP2C9 *2 + *3 + *8 are associated with _____ dose of warfarin as compared to CYP2C9 *1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "e448b950-3e5e-478a-bade-73dff0a4119a", "source_file": "PMC4706412.json", "annotation_id": "1447682605", "pmid": "26745506", "original_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.", "blanked_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased _____ warfarin as compared to CYP2C9 *1.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "381a8d1f-d056-4da7-8bb6-71e717657714", "source_file": "PMC4706412.json", "annotation_id": "1447682605", "pmid": "26745506", "original_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.", "blanked_sentence": "CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "ef837a3a-fb99-4add-a749-2f8979888d67", "source_file": "PMC4706412.json", "annotation_id": "1447682688", "pmid": "26745506", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with decreased dose of _____ as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "74ee0a62-b308-4201-92c1-bcf5607b8686", "source_file": "PMC4706412.json", "annotation_id": "1447682688", "pmid": "26745506", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.", "blanked_sentence": "Genotypes _____ are associated with decreased dose of warfarin as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT + TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "7261a1c2-109d-41d9-b5a2-25fa7d08e576", "source_file": "PMC4706412.json", "annotation_id": "1447682688", "pmid": "26745506", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with _____ dose of warfarin as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "c33296b8-0740-438c-8d87-9efc2db04dac", "source_file": "PMC4706412.json", "annotation_id": "1447682688", "pmid": "26745506", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with decreased _____ warfarin as compared to genotype CC.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "6b505252-8f02-41f2-8c0c-967df636d0b8", "source_file": "PMC4706412.json", "annotation_id": "1447682688", "pmid": "26745506", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "c2aad3f6-a0f6-49e6-a3b1-1963c67a08b8", "source_file": "PMC4706412.json", "annotation_id": "1447682722", "pmid": "26745506", "original_sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.", "blanked_sentence": "Genotypes AA + AG are associated with increased dose of _____ as compared to genotype GG.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "cfc5b0ce-61e4-47e7-be1c-11601998dfba", "source_file": "PMC4706412.json", "annotation_id": "1447682722", "pmid": "26745506", "original_sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.", "blanked_sentence": "Genotypes _____ are associated with increased dose of warfarin as compared to genotype GG.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AA + AG"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "fd41a53f-9172-4ff6-af56-2b0c0b6952e3", "source_file": "PMC4706412.json", "annotation_id": "1447682722", "pmid": "26745506", "original_sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.", "blanked_sentence": "Genotypes AA + AG are associated with _____ dose of warfarin as compared to genotype GG.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "eb7dad77-5a96-4660-be4e-3bcd21b19b37", "source_file": "PMC4706412.json", "annotation_id": "1447682722", "pmid": "26745506", "original_sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.", "blanked_sentence": "Genotypes AA + AG are associated with increased _____ warfarin as compared to genotype GG.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "e7cd9fb5-dbbd-4e5f-a89e-61e8091b796b", "source_file": "PMC4706412.json", "annotation_id": "1447682722", "pmid": "26745506", "original_sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.", "blanked_sentence": "Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["GG"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "153400fc-30ac-4ab8-aa4c-48a8e70a2e19", "source_file": "PMC4916189.json", "annotation_id": "1448993783", "pmid": "26715213", "original_sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with _____ in people with HIV as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b76e4b9d-2029-4adf-bf8b-e47bcca0c75d", "source_file": "PMC4916189.json", "annotation_id": "1448993783", "pmid": "26715213", "original_sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 _____ is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*9"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "00ce5bb2-b531-49c0-aade-37f8f648c2e4", "source_file": "PMC4916189.json", "annotation_id": "1448993783", "pmid": "26715213", "original_sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *9 is associated with _____ likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8d5d7ca3-d62d-461a-95dd-ee7065fee387", "source_file": "PMC4916189.json", "annotation_id": "1448993783", "pmid": "26715213", "original_sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.", "blanked_sentence": "CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a6e9412d-697a-47d8-a7ee-27a70e7240c0", "source_file": "PMC4916189.json", "annotation_id": "1448993767", "pmid": "26715213", "original_sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with _____ in people with HIV Infections as compared to genotype GG.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "231ceb5a-2f7c-47bf-a8a1-9d3d5fe0a6db", "source_file": "PMC4916189.json", "annotation_id": "1448993767", "pmid": "26715213", "original_sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotypes _____ are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["GT + TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2e51c0ca-d9e9-4841-b2ee-b695a65dd8af", "source_file": "PMC4916189.json", "annotation_id": "1448993767", "pmid": "26715213", "original_sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotypes GT + TT are associated with _____ likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7bb6bc11-d99a-4846-9908-11438a73a226", "source_file": "PMC4916189.json", "annotation_id": "1448993767", "pmid": "26715213", "original_sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["GG"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a47a89ba-9d88-4f15-bcb0-9deaac800311", "source_file": "PMC4916189.json", "annotation_id": "1448993794", "pmid": "26715213", "original_sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with _____ in people with HIV Infections as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "592d9d2c-6f69-4ece-b3b7-a0b486e1f6e5", "source_file": "PMC4916189.json", "annotation_id": "1448993794", "pmid": "26715213", "original_sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.", "blanked_sentence": "Genotype _____ is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a99b4187-9da2-4a36-b401-9d87e42696e1", "source_file": "PMC4916189.json", "annotation_id": "1448993794", "pmid": "26715213", "original_sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with _____ likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c1ad7894-ac54-4d97-80ac-823cefc05f5c", "source_file": "PMC4916189.json", "annotation_id": "1448993794", "pmid": "26715213", "original_sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC + CT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9281e239-9b54-4332-84c2-2d1e1ce0267c", "source_file": "PMC4916189.json", "annotation_id": "1448993759", "pmid": "26715213", "original_sentence": "Allele T is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G.", "blanked_sentence": "Allele T is not associated with virological response when treated with _____ in people with HIV Infections as compared to allele G.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "12749616-ac06-4d2c-b351-c66e0bd2a481", "source_file": "PMC4916189.json", "annotation_id": "1448993759", "pmid": "26715213", "original_sentence": "Allele T is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G.", "blanked_sentence": "Allele _____ is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["T"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9f00e8a6-23cf-4826-8ab2-afe3ecdbee3e", "source_file": "PMC4916189.json", "annotation_id": "1448993759", "pmid": "26715213", "original_sentence": "Allele T is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G.", "blanked_sentence": "Allele T is not associated with virolo_____ical response when treated with efavirenz in people with HIV Infections as compared to allele G.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["G"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "093988ec-1f9f-41bc-9d02-48e2456c7a83", "source_file": "PMC4916189.json", "annotation_id": "1448993831", "pmid": "26715213", "original_sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with _____ in people with HIV Infections as compared to genotype GG.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f189c564-86f0-4380-8237-b69bb941aa65", "source_file": "PMC4916189.json", "annotation_id": "1448993831", "pmid": "26715213", "original_sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotype _____ are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AA"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bc2f6bb4-ac04-4401-a1a5-f194f38bf622", "source_file": "PMC4916189.json", "annotation_id": "1448993831", "pmid": "26715213", "original_sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotype AA are associated with _____ risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c972527e-9d6a-4338-91d1-35699ff3590a", "source_file": "PMC4916189.json", "annotation_id": "1448993831", "pmid": "26715213", "original_sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "blanked_sentence": "Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["GG"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cbe3a8b7-b837-4897-9aef-9a4cb55b244d", "source_file": "PMC4916189.json", "annotation_id": "1448993810", "pmid": "26715213", "original_sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with _____ in people with HIV Infections as compared to genotype TT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1cbe32a5-8a62-4af2-9c47-ec5831aabc0f", "source_file": "PMC4916189.json", "annotation_id": "1448993810", "pmid": "26715213", "original_sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.", "blanked_sentence": "Genotypes _____ are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CC + CT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "392a9791-eb2a-4ccb-be83-92d8d62f7aba", "source_file": "PMC4916189.json", "annotation_id": "1448993810", "pmid": "26715213", "original_sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT are associated with _____ risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e4788b81-c4ec-4619-a159-4ce4486f84cf", "source_file": "PMC4916189.json", "annotation_id": "1448993810", "pmid": "26715213", "original_sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.", "blanked_sentence": "Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["TT"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4cfc70ea-7726-4d8f-9e77-07549a8a95e8", "source_file": "PMC4916189.json", "annotation_id": "1448993820", "pmid": "26715213", "original_sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with _____ in people with HIV Infections as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["efavirenz"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "49c372d5-b673-42a2-9edc-97a684f1ea2f", "source_file": "PMC4916189.json", "annotation_id": "1448993820", "pmid": "26715213", "original_sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.", "blanked_sentence": "Genotypes _____ are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT + TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5fc779db-76c8-44f2-ae28-ee5ec27ba9d6", "source_file": "PMC4916189.json", "annotation_id": "1448993820", "pmid": "26715213", "original_sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with _____ risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8a85669b-2587-4388-a586-8b19140fb08c", "source_file": "PMC4916189.json", "annotation_id": "1448993820", "pmid": "26715213", "original_sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "153addd1-3541-4bc8-8466-6e512fe15d6d", "source_file": "PMC5508045.json", "annotation_id": "1448624157", "pmid": "28550460", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with decreased dose of _____ in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "1e31e3ac-e0c8-4ab5-99bd-8ac58c76c26f", "source_file": "PMC5508045.json", "annotation_id": "1448624157", "pmid": "28550460", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotypes _____ are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT + TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "3225eb16-6576-4b34-9266-641107583e8b", "source_file": "PMC5508045.json", "annotation_id": "1448624157", "pmid": "28550460", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with _____ dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "9e3e44c6-511d-495a-9079-1307d9f549b5", "source_file": "PMC5508045.json", "annotation_id": "1448624157", "pmid": "28550460", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with decreased _____ warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "78fc8382-5cb3-4ab8-b21d-3924f836476f", "source_file": "PMC5508045.json", "annotation_id": "1448624157", "pmid": "28550460", "original_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "60b0f360-d5d0-4dea-a5c3-bd6f0ccac614", "source_file": "PMC5508045.json", "annotation_id": "1448624168", "pmid": "28550460", "original_sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanked_sentence": "Genotypes AC + CC are associated with decreased dose of _____ in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "68c8c038-11a5-40b8-9cf7-846feb052bc7", "source_file": "PMC5508045.json", "annotation_id": "1448624168", "pmid": "28550460", "original_sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanked_sentence": "Genotypes _____ are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AC + CC"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "c36194fe-39c3-4e48-abf9-fb1910e89b6d", "source_file": "PMC5508045.json", "annotation_id": "1448624168", "pmid": "28550460", "original_sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanked_sentence": "Genotypes AC + CC are associated with _____ dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "925f9f82-7486-4eae-bbf9-3d3ca14135f4", "source_file": "PMC5508045.json", "annotation_id": "1448624168", "pmid": "28550460", "original_sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanked_sentence": "Genotypes AC + CC are associated with decreased _____ warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "5a8a0308-652a-4203-93ec-a4342d921cdb", "source_file": "PMC5508045.json", "annotation_id": "1448624168", "pmid": "28550460", "original_sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.", "blanked_sentence": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "29c08aba-8ac1-4274-b704-8e00bfd2ecd4", "source_file": "PMC5508045.json", "annotation_id": "1448624178", "pmid": "28550460", "original_sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotype TT is associated with increased dose of _____ in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "6b892001-8a54-4d1c-be01-01ba2ad26e79", "source_file": "PMC5508045.json", "annotation_id": "1448624178", "pmid": "28550460", "original_sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotype _____ is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "2db82f9f-4d9f-4afd-9886-13f7f1db6bba", "source_file": "PMC5508045.json", "annotation_id": "1448624178", "pmid": "28550460", "original_sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotype TT is associated with _____ dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "ba4630c6-5108-4436-b15e-866de2c2b28e", "source_file": "PMC5508045.json", "annotation_id": "1448624178", "pmid": "28550460", "original_sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotype TT is associated with increased _____ warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "62640190-7167-4347-ac72-2f8cd72ae711", "source_file": "PMC5508045.json", "annotation_id": "1448624178", "pmid": "28550460", "original_sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.", "blanked_sentence": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "bc70e590-b6d8-4c92-b1da-c580afebcb35", "source_file": "PMC5508045.json", "annotation_id": "1448624188", "pmid": "28550460", "original_sentence": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanked_sentence": "Allele C is not associated with dose of _____ in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["warfarin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "54c3b7d5-81f8-4246-9377-4f34a5e7b543", "source_file": "PMC5508045.json", "annotation_id": "1448624188", "pmid": "28550460", "original_sentence": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanked_sentence": "Allele _____ is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["C"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "008b5a07-0710-4a81-be71-71c5ac3b2507", "source_file": "PMC5508045.json", "annotation_id": "1448624188", "pmid": "28550460", "original_sentence": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanked_sentence": "Allele C is not associated with _____ warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "da72e341-afa0-41ba-8080-ea404e7a6c76", "source_file": "PMC5508045.json", "annotation_id": "1448624188", "pmid": "28550460", "original_sentence": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanked_sentence": "Allele C is no_____ associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["T"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "9c132dd9-5d70-409c-bb9b-63147e605067", "source_file": "PMC554812.json", "annotation_id": "981345654", "pmid": "15743917", "original_sentence": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["allopurinol"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a7bf9066-15e2-410c-960b-0a26fe370195", "source_file": "PMC554812.json", "annotation_id": "981345654", "pmid": "15743917", "original_sentence": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-B _____ is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*58:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2226914e-7932-4404-a3bc-575532d20ff2", "source_file": "PMC554812.json", "annotation_id": "981345654", "pmid": "15743917", "original_sentence": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-B *58:01 is associated with _____ risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "131a234b-11c7-4961-9dc8-fa937b28f020", "source_file": "PMC554812.json", "annotation_id": "981345654", "pmid": "15743917", "original_sentence": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-B *58:01 is associated with increased risk of _____ when treated with allopurinol.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Severe Cutaneous Adverse Reactions"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "55a39164-ab12-44ca-863d-a35d1a2feacb", "source_file": "PMC554812.json", "annotation_id": "1184755073", "pmid": "15743917", "original_sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["allopurinol"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "31f2d6ec-a528-4c81-8480-2e2984999207", "source_file": "PMC554812.json", "annotation_id": "1184755073", "pmid": "15743917", "original_sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-DRB1 _____ is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*03:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "42b7f898-898b-4a42-8cdd-316e7af6e7f7", "source_file": "PMC554812.json", "annotation_id": "1184755073", "pmid": "15743917", "original_sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-DRB1 *03:01 is associated with _____ risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7d37afcb-6b0e-49ce-a73f-70a518e7cdc5", "source_file": "PMC554812.json", "annotation_id": "1184755073", "pmid": "15743917", "original_sentence": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-DRB1 *03:01 is associated with increased risk of _____ when treated with allopurinol.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Severe Cutaneous Adverse Reactions"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "fef3cd61-1a65-4152-92d9-5d2ec3324b28", "source_file": "PMC554812.json", "annotation_id": "1184755032", "pmid": "15743917", "original_sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["allopurinol"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8f742d2c-1b98-4a1d-b2c9-78442c864226", "source_file": "PMC554812.json", "annotation_id": "1184755032", "pmid": "15743917", "original_sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-C _____ is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*03:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "acf442fb-e0e9-4967-be67-e5e15c56a94c", "source_file": "PMC554812.json", "annotation_id": "1184755032", "pmid": "15743917", "original_sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-C *03:02 is associated with _____ risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "33335794-8cae-4b2f-9360-7c9578dd991f", "source_file": "PMC554812.json", "annotation_id": "1184755032", "pmid": "15743917", "original_sentence": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-C *03:02 is associated with increased risk of _____ when treated with allopurinol.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Severe Cutaneous Adverse Reactions"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b2990032-7856-4c23-bf20-17fa0bbea340", "source_file": "PMC554812.json", "annotation_id": "1184755056", "pmid": "15743917", "original_sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["allopurinol"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e34b6bc9-4f23-4361-a7db-a90251e41f64", "source_file": "PMC554812.json", "annotation_id": "1184755056", "pmid": "15743917", "original_sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-A _____ is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*33:03"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "422f6454-f36d-42e1-b107-e9d374ea82a9", "source_file": "PMC554812.json", "annotation_id": "1184755056", "pmid": "15743917", "original_sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-A *33:03 is associated with _____ risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "22c0b2da-89c0-4713-a078-9232eb5207fd", "source_file": "PMC554812.json", "annotation_id": "1184755056", "pmid": "15743917", "original_sentence": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.", "blanked_sentence": "HLA-A *33:03 is associated with increased risk of _____ when treated with allopurinol.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Severe Cutaneous Adverse Reactions"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "be5903d8-f32a-4889-9b3d-17f4efd6ba22", "source_file": "PMC554812.json", "annotation_id": "1184755144", "pmid": "15743917", "original_sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.", "blanked_sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with _____ as compared to allele G.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["allopurinol"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a1a22873-7bb0-4710-9321-a2167775db61", "source_file": "PMC554812.json", "annotation_id": "1184755144", "pmid": "15743917", "original_sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.", "blanked_sentence": "_____llele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["A"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5ae530ab-8d3b-4868-965b-fc292b850fa6", "source_file": "PMC554812.json", "annotation_id": "1184755144", "pmid": "15743917", "original_sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.", "blanked_sentence": "Allele A is associated with _____ when treated with allopurinol as compared to allele G.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Severe Cutaneous Adverse Reactions"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1e2bda81-417f-4b66-b377-1abd4dceff51", "source_file": "PMC554812.json", "annotation_id": "1184755144", "pmid": "15743917", "original_sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.", "blanked_sentence": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["G"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8c5a5389-41b5-4427-9a3f-f648520049eb", "source_file": "PMC5561238.json", "annotation_id": "1448926055", "pmid": "28819312", "original_sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f9a8416d-ea19-4b99-94d3-d0847ff74cb5", "source_file": "PMC5561238.json", "annotation_id": "1448926055", "pmid": "28819312", "original_sentence": "HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*67:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2fbc87c5-bccd-4873-aaee-caed3f9d3ad3", "source_file": "PMC5561238.json", "annotation_id": "1448926065", "pmid": "28819312", "original_sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "6969101b-1c23-4a73-b51a-b3a1de6a4c69", "source_file": "PMC5561238.json", "annotation_id": "1448926065", "pmid": "28819312", "original_sentence": "HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*78:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "39c6a53e-ac6e-4f3c-9985-0e526afe24fe", "source_file": "PMC5561238.json", "annotation_id": "1448925992", "pmid": "28819312", "original_sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0589e5a3-fae0-4272-8939-26a897e0b80b", "source_file": "PMC5561238.json", "annotation_id": "1448925992", "pmid": "28819312", "original_sentence": "HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*51:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "32d8041b-1509-4316-8cb6-9ffbc27ba13f", "source_file": "PMC5561238.json", "annotation_id": "1448926045", "pmid": "28819312", "original_sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "58d7c9c2-ec88-46fd-97cb-0013385fd492", "source_file": "PMC5561238.json", "annotation_id": "1448926045", "pmid": "28819312", "original_sentence": "HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*56:06"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ded7a87d-7c6d-4103-b5a5-a405ee8a8d3e", "source_file": "PMC5561238.json", "annotation_id": "1448926109", "pmid": "28819312", "original_sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "dd2566ff-dd6a-43b6-8a85-9e38e309dcc9", "source_file": "PMC5561238.json", "annotation_id": "1448926109", "pmid": "28819312", "original_sentence": "HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*39:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "971a293a-f058-4872-8ff9-f60469286610", "source_file": "PMC5561238.json", "annotation_id": "1448925913", "pmid": "28819312", "original_sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "acba8996-23db-417f-94ba-4703e39b3c6e", "source_file": "PMC5561238.json", "annotation_id": "1448925913", "pmid": "28819312", "original_sentence": "HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*05:09"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "abe6b8ab-dd31-4106-ab7a-769bd3c8833a", "source_file": "PMC5561238.json", "annotation_id": "1448926229", "pmid": "28819312", "original_sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "adeeb00a-117d-4dad-b776-0186ef9575a0", "source_file": "PMC5561238.json", "annotation_id": "1448926229", "pmid": "28819312", "original_sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:32"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f5d66482-3875-40ce-bf07-3b208c3231a0", "source_file": "PMC5561238.json", "annotation_id": "1448926229", "pmid": "28819312", "original_sentence": "HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:32 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "529c3cec-d724-425a-8106-ddd49ea439f8", "source_file": "PMC5561238.json", "annotation_id": "1448925903", "pmid": "28819312", "original_sentence": "HLA-C *05:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *05:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3a2f7973-88a6-4256-b386-acc980a8a788", "source_file": "PMC5561238.json", "annotation_id": "1448925903", "pmid": "28819312", "original_sentence": "HLA-C *05:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*05:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5455feca-9824-4e5e-b53c-a136d791a60b", "source_file": "PMC5561238.json", "annotation_id": "1448925982", "pmid": "28819312", "original_sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ea761fd0-bba1-46a5-ac39-9d19fa7700f3", "source_file": "PMC5561238.json", "annotation_id": "1448925982", "pmid": "28819312", "original_sentence": "HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*51:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7de361ae-393a-47ce-95af-c86002bdf60e", "source_file": "PMC5561238.json", "annotation_id": "1448926239", "pmid": "28819312", "original_sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7dfe40bd-3cd8-45ac-b6b5-90269d9d4ec5", "source_file": "PMC5561238.json", "annotation_id": "1448926239", "pmid": "28819312", "original_sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:35"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cded013f-61fb-425c-b6c0-445810688608", "source_file": "PMC5561238.json", "annotation_id": "1448926239", "pmid": "28819312", "original_sentence": "HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:35 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bf973b97-5fd9-47a5-95fe-0f06c9960df2", "source_file": "PMC5561238.json", "annotation_id": "1448926169", "pmid": "28819312", "original_sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "28ce81cb-d9c4-4e9a-a732-ef93deb22d5d", "source_file": "PMC5561238.json", "annotation_id": "1448926169", "pmid": "28819312", "original_sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:12"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "17ba4d80-dce9-48f4-82e8-d221c46bbbc4", "source_file": "PMC5561238.json", "annotation_id": "1448926169", "pmid": "28819312", "original_sentence": "HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:12 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f338b3c0-e67a-4b1a-8608-56a3ca78e1de", "source_file": "PMC5561238.json", "annotation_id": "1448926299", "pmid": "28819312", "original_sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ea29586a-e17b-46d8-ac37-8d1cecd716db", "source_file": "PMC5561238.json", "annotation_id": "1448926299", "pmid": "28819312", "original_sentence": "HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*08:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f530b1f4-536c-4c6d-b86a-ae56c66009cb", "source_file": "PMC5561238.json", "annotation_id": "1448925972", "pmid": "28819312", "original_sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "32db9944-957b-48c1-9aeb-ea6d3a5efa60", "source_file": "PMC5561238.json", "annotation_id": "1448925972", "pmid": "28819312", "original_sentence": "HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*39:10"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b2bc40bf-9c80-4612-9a8d-0f272ea353f4", "source_file": "PMC5561238.json", "annotation_id": "1448926099", "pmid": "28819312", "original_sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "40e67962-192c-4c61-8b85-4d0017fa8b8e", "source_file": "PMC5561238.json", "annotation_id": "1448926099", "pmid": "28819312", "original_sentence": "HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*38:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8d25575f-2e3c-43e6-98d1-a541b312fbf0", "source_file": "PMC5561238.json", "annotation_id": "1448926089", "pmid": "28819312", "original_sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b494cdb7-7627-45b6-aee4-4872ea55bc6e", "source_file": "PMC5561238.json", "annotation_id": "1448926089", "pmid": "28819312", "original_sentence": "HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*38:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e4ead78b-51ee-426d-b1b3-e7af2d384963", "source_file": "PMC5561238.json", "annotation_id": "1448926289", "pmid": "28819312", "original_sentence": "HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b377a1c9-9340-40ce-94dc-6b5b418d8111", "source_file": "PMC5561238.json", "annotation_id": "1448926289", "pmid": "28819312", "original_sentence": "HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*04:04"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "625bf017-40b7-4018-8e11-aa5fd512eb49", "source_file": "PMC5561238.json", "annotation_id": "1448926035", "pmid": "28819312", "original_sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e851f904-5acd-4530-a105-795c35b8b07a", "source_file": "PMC5561238.json", "annotation_id": "1448926035", "pmid": "28819312", "original_sentence": "HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*56:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "64436972-68e4-4b4a-92ca-bab63b60c405", "source_file": "PMC5561238.json", "annotation_id": "1448925958", "pmid": "28819312", "original_sentence": "HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4cb72b85-84be-4479-8242-5c2ff93c1185", "source_file": "PMC5561238.json", "annotation_id": "1448925958", "pmid": "28819312", "original_sentence": "HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*35:05"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "6ec13409-ac39-47c1-8355-a611a90ac81f", "source_file": "PMC5561238.json", "annotation_id": "1448926269", "pmid": "28819312", "original_sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ace7ab16-b549-46e3-b758-4e0b18e855c7", "source_file": "PMC5561238.json", "annotation_id": "1448926269", "pmid": "28819312", "original_sentence": "HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*01:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ceb4b05f-d42b-4b74-9cd6-21ee019adbe6", "source_file": "PMC5561238.json", "annotation_id": "1448926139", "pmid": "28819312", "original_sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9551b386-ebe0-4356-9c57-aba01e87b082", "source_file": "PMC5561238.json", "annotation_id": "1448926139", "pmid": "28819312", "original_sentence": "HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*39:09"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "dc77b240-023d-4735-b2e5-6501603e4552", "source_file": "PMC5561238.json", "annotation_id": "1448926159", "pmid": "28819312", "original_sentence": "HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1b3716c0-b821-4379-9079-e4f8d93d8c50", "source_file": "PMC5561238.json", "annotation_id": "1448926159", "pmid": "28819312", "original_sentence": "HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8f35778d-47f2-4709-ac93-14188ffb443e", "source_file": "PMC5561238.json", "annotation_id": "1448926159", "pmid": "28819312", "original_sentence": "HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:01 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b78d9a86-0f90-450f-8e83-6475b4180c0a", "source_file": "PMC5561238.json", "annotation_id": "1448926209", "pmid": "28819312", "original_sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "2e0704eb-c534-4021-800f-172629658b0f", "source_file": "PMC5561238.json", "annotation_id": "1448926209", "pmid": "28819312", "original_sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:27"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7668d652-603a-499a-a4f6-a7faa1100dcb", "source_file": "PMC5561238.json", "annotation_id": "1448926209", "pmid": "28819312", "original_sentence": "HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:27 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bad9f733-994d-4176-9d3f-7194d70ed90b", "source_file": "PMC5561238.json", "annotation_id": "1448998275", "pmid": "28819312", "original_sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "08d1a25e-74ce-4ccb-8d4f-738402d54a2d", "source_file": "PMC5561238.json", "annotation_id": "1448998275", "pmid": "28819312", "original_sentence": "HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*35:10"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "da1fccd9-a853-4dce-9098-e9c8563078e4", "source_file": "PMC5561238.json", "annotation_id": "1448925883", "pmid": "28819312", "original_sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4675d809-3e6f-4f00-8136-e2f56d8b307d", "source_file": "PMC5561238.json", "annotation_id": "1448925883", "pmid": "28819312", "original_sentence": "HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*04:06"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e79ef822-47c7-4386-81c6-bf1f885519bd", "source_file": "PMC5561238.json", "annotation_id": "1448926149", "pmid": "28819312", "original_sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e97402d9-e0c6-4289-965b-fc6954e144f5", "source_file": "PMC5561238.json", "annotation_id": "1448926149", "pmid": "28819312", "original_sentence": "HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*57:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3067c162-4f11-435e-8eb4-67c279a3368c", "source_file": "PMC5561238.json", "annotation_id": "1448925893", "pmid": "28819312", "original_sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5e4fab1d-3639-466b-bab4-3dce6ca032af", "source_file": "PMC5561238.json", "annotation_id": "1448925893", "pmid": "28819312", "original_sentence": "HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*04:07"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "d12f657a-4639-49a6-824a-337fec7ff660", "source_file": "PMC5561238.json", "annotation_id": "1448926022", "pmid": "28819312", "original_sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e6dc0c30-596d-4ac3-b329-50b60c7eb22a", "source_file": "PMC5561238.json", "annotation_id": "1448926022", "pmid": "28819312", "original_sentence": "HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*55:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a2fcb7a9-5ff1-49e6-a63b-73ac407328cc", "source_file": "PMC5561238.json", "annotation_id": "1448926279", "pmid": "28819312", "original_sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "d76cea7b-7abd-41fd-b8de-5a0f647cfc77", "source_file": "PMC5561238.json", "annotation_id": "1448926279", "pmid": "28819312", "original_sentence": "HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*01:03"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "873340fb-797f-44e8-8c00-4aae212b5b81", "source_file": "PMC5561238.json", "annotation_id": "1448926012", "pmid": "28819312", "original_sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "8060276a-6355-4c1c-9892-35c418a8d03e", "source_file": "PMC5561238.json", "annotation_id": "1448926012", "pmid": "28819312", "original_sentence": "HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*55:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c239d08c-c5de-4eae-bd1c-1a6deca6b8c9", "source_file": "PMC5561238.json", "annotation_id": "1448926075", "pmid": "28819312", "original_sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "75c2b01d-e692-4ccb-94ce-6fd2cf50c64f", "source_file": "PMC5561238.json", "annotation_id": "1448926075", "pmid": "28819312", "original_sentence": "HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*13:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "062a523d-caab-4935-a742-84dddf167ff2", "source_file": "PMC5561238.json", "annotation_id": "1448926199", "pmid": "28819312", "original_sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "80e96ea8-9600-4d3f-b42b-938f8eda850b", "source_file": "PMC5561238.json", "annotation_id": "1448926199", "pmid": "28819312", "original_sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:25"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a4a23992-8918-4bc7-a69a-c8747743046a", "source_file": "PMC5561238.json", "annotation_id": "1448926199", "pmid": "28819312", "original_sentence": "HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:25 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cb490a1e-b696-4958-9009-f3a3fec3a6c4", "source_file": "PMC5561238.json", "annotation_id": "1448926129", "pmid": "28819312", "original_sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "34ffae94-9d08-445f-ab64-4c9f713702a7", "source_file": "PMC5561238.json", "annotation_id": "1448926129", "pmid": "28819312", "original_sentence": "HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*39:06"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0031f9ad-f435-496f-8437-408472f06b5b", "source_file": "PMC5561238.json", "annotation_id": "1448925873", "pmid": "28819312", "original_sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "29c22129-b350-4358-8699-351dfc0a43aa", "source_file": "PMC5561238.json", "annotation_id": "1448925873", "pmid": "28819312", "original_sentence": "HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*04:03"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ecfedc52-fd9a-4a4f-88e0-edfa026e6ffa", "source_file": "PMC5561238.json", "annotation_id": "1448926002", "pmid": "28819312", "original_sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b5fb6176-12ce-4bfc-b376-4cb9e29b714d", "source_file": "PMC5561238.json", "annotation_id": "1448926002", "pmid": "28819312", "original_sentence": "HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*54:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "88609c48-c1ca-4c61-8fdf-fe7b336811c0", "source_file": "PMC5561238.json", "annotation_id": "1448926259", "pmid": "28819312", "original_sentence": "HLA-DRB1 *01:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *01:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c7182124-9470-423e-a8f0-13fb1f4a49ba", "source_file": "PMC5561238.json", "annotation_id": "1448926259", "pmid": "28819312", "original_sentence": "HLA-DRB1 *01:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*01:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "5b479252-6096-4476-bdb4-546baf6c4882", "source_file": "PMC5561238.json", "annotation_id": "1448926249", "pmid": "28819312", "original_sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "c680e5ea-a93e-47b1-858c-e6d2bcfeeb34", "source_file": "PMC5561238.json", "annotation_id": "1448926249", "pmid": "28819312", "original_sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*52:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "35657a74-6911-4d1f-af97-c167b55f8877", "source_file": "PMC5561238.json", "annotation_id": "1448926249", "pmid": "28819312", "original_sentence": "HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *52:01 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f471beca-1874-4abb-9a88-c9fa041491f5", "source_file": "PMC5561238.json", "annotation_id": "1448926309", "pmid": "28819312", "original_sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f8f4055a-1d97-4caa-9f8c-6e81309826aa", "source_file": "PMC5561238.json", "annotation_id": "1448926309", "pmid": "28819312", "original_sentence": "HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-DRB1 _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*10:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "f0324771-2d22-4485-a63b-e286b70c7060", "source_file": "PMC5561238.json", "annotation_id": "1448925862", "pmid": "28819312", "original_sentence": "HLA-C *04:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *04:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "15e1c9e3-f448-4ba5-b78d-4e8462ef8f8e", "source_file": "PMC5561238.json", "annotation_id": "1448925862", "pmid": "28819312", "original_sentence": "HLA-C *04:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*04:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "cdf2e6c4-879e-4d4f-9ea0-51ffcf7f8685", "source_file": "PMC5561238.json", "annotation_id": "1448926119", "pmid": "28819312", "original_sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "94b95946-1250-4c37-a04c-500eef53ae1f", "source_file": "PMC5561238.json", "annotation_id": "1448926119", "pmid": "28819312", "original_sentence": "HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*39:05"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "66905a82-c7f6-44ab-ac40-e8e2ea2a126a", "source_file": "PMC5561238.json", "annotation_id": "1448925923", "pmid": "28819312", "original_sentence": "HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "3339f9e8-54f9-45c8-b6b5-3dabc00c335e", "source_file": "PMC5561238.json", "annotation_id": "1448925923", "pmid": "28819312", "original_sentence": "HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-C _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*18:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e1e3b807-4039-4a18-b28f-26ae712533d1", "source_file": "PMC5561238.json", "annotation_id": "1448926179", "pmid": "28819312", "original_sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b17f20b3-33fe-43f8-9cb0-eff9b6e5e4b5", "source_file": "PMC5561238.json", "annotation_id": "1448926179", "pmid": "28819312", "original_sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B _____ is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*15:24"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ffb32b88-bd39-4749-8d46-52e4005838e8", "source_file": "PMC5561238.json", "annotation_id": "1448926179", "pmid": "28819312", "original_sentence": "HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanked_sentence": "HLA-B *15:24 is associated with _____ risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "793458b1-1fff-4a38-93f9-7fbff858ffe4", "source_file": "PMC5561238.json", "annotation_id": "1449155757", "pmid": "28819312", "original_sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.", "blanked_sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with _____ in people with HIV Infections as compared to allele T.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b9a268bf-68fd-43a3-8deb-0a7e9f12ea06", "source_file": "PMC5561238.json", "annotation_id": "1449155757", "pmid": "28819312", "original_sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.", "blanked_sentence": "Allele _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["C"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4a0404a9-2683-46ed-8e54-e0650f5e4e6e", "source_file": "PMC5561238.json", "annotation_id": "1449155757", "pmid": "28819312", "original_sentence": "Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.", "blanked_sentence": "Allele C is associa_____ed with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["T"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9fc3f421-5dc5-4dd6-9093-3702acf5f859", "source_file": "PMC5561238.json", "annotation_id": "1449155771", "pmid": "28819312", "original_sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.", "blanked_sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with _____ in people with HIV Infections as compared to allele G.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["nevirapine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0ae1862e-edfa-4ffc-84ca-91d6f88764ac", "source_file": "PMC5561238.json", "annotation_id": "1449155771", "pmid": "28819312", "original_sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.", "blanked_sentence": "Allele _____ is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["T"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "02882915-3807-434c-9b57-cf892f87b725", "source_file": "PMC5561238.json", "annotation_id": "1449155771", "pmid": "28819312", "original_sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.", "blanked_sentence": "Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Dru_____ Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["G"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ae52621b-66a9-4fc1-8021-20ec0d052074", "source_file": "PMC6435416.json", "annotation_id": "1450932846", "pmid": "30661084", "original_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanked_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to _____ in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["risperidone"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "d221cabe-3203-4ce0-9fb0-bbe0532bb752", "source_file": "PMC6435416.json", "annotation_id": "1450932846", "pmid": "30661084", "original_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanked_sentence": "CYP2D6 _____ (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b5c86a28-c311-4e01-b545-977193fdd4f0", "source_file": "PMC6435416.json", "annotation_id": "1450932846", "pmid": "30661084", "original_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanked_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with _____ likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e0aa599a-9249-435a-a867-2da662885df3", "source_file": "PMC6435416.json", "annotation_id": "1450932846", "pmid": "30661084", "original_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanked_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of _____ due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["adverse events"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "14a1bc7c-58b2-43b3-9912-056ae0a6a662", "source_file": "PMC6435416.json", "annotation_id": "1450932846", "pmid": "30661084", "original_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanked_sentence": "CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 _____ (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["*1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "42045c67-a755-4767-8c33-7cbdfb13e5ad", "source_file": "PMC6465603.json", "annotation_id": "1451237464", "pmid": "31024313", "original_sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanked_sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with _____ in people with Hepatitis, Autoimmune as compared to allele T.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["azathioprine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "90c03df1-e89f-43db-a56b-655bfb749ee4", "source_file": "PMC6465603.json", "annotation_id": "1451237464", "pmid": "31024313", "original_sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanked_sentence": "Allele _____ is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["C"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "64ca5423-c999-4746-a412-47dd0e468a29", "source_file": "PMC6465603.json", "annotation_id": "1451237464", "pmid": "31024313", "original_sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanked_sentence": "Allele C is not associated with _____ likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1f437c39-03ff-4fa0-bc53-edcb82e621ff", "source_file": "PMC6465603.json", "annotation_id": "1451237464", "pmid": "31024313", "original_sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanked_sentence": "Allele C is not associated with increased likelihood of _____ when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Leukopenia"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "09af035d-0abf-486f-b43c-1766eaca7287", "source_file": "PMC6465603.json", "annotation_id": "1451237464", "pmid": "31024313", "original_sentence": "Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanked_sentence": "Allele C is no_____ associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["T"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "4d28606c-a86b-4e9a-ad1c-44bb8160220a", "source_file": "PMC6465603.json", "annotation_id": "1451237500", "pmid": "31024313", "original_sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with _____ in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["azathioprine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "a64dbc06-83a0-4ec7-9f23-660c1ce6ff69", "source_file": "PMC6465603.json", "annotation_id": "1451237500", "pmid": "31024313", "original_sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanked_sentence": "Genotypes _____ is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT + TT"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e7d30052-7c55-4e13-a035-253c752f53f8", "source_file": "PMC6465603.json", "annotation_id": "1451237500", "pmid": "31024313", "original_sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with _____ likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "59bc35bd-ca76-416d-8c1d-7007f7e56d2e", "source_file": "PMC6465603.json", "annotation_id": "1451237500", "pmid": "31024313", "original_sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with increased likelihood of _____ when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Leukopenia"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "d3f02af7-1107-4f76-bd6a-9077b09a76bc", "source_file": "PMC6465603.json", "annotation_id": "1451237500", "pmid": "31024313", "original_sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.", "blanked_sentence": "Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "be2806b4-bf70-4be3-a164-693cfb513217", "source_file": "PMC6714829.json", "annotation_id": "1451226960", "pmid": "30336686", "original_sentence": "Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with increased response to _____ in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["simvastatin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "b218427a-c403-417e-b667-2d5d17db7c8f", "source_file": "PMC6714829.json", "annotation_id": "1451226960", "pmid": "30336686", "original_sentence": "Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanked_sentence": "Genotype _____ is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["TT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "3bbc724e-f908-4ad3-b18a-6d862075fce8", "source_file": "PMC6714829.json", "annotation_id": "1451226960", "pmid": "30336686", "original_sentence": "Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with _____ response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "b156645f-0e61-40ba-a987-ce5d9e33b63f", "source_file": "PMC6714829.json", "annotation_id": "1451226960", "pmid": "30336686", "original_sentence": "Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with increased _____ simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["response to"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "4ea0df68-89a6-4038-9539-aec563914e30", "source_file": "PMC6714829.json", "annotation_id": "1451226960", "pmid": "30336686", "original_sentence": "Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.", "blanked_sentence": "Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC + CT"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "d4546bc9-8440-4931-abcb-9ac2757c1bbb", "source_file": "PMC6714829.json", "annotation_id": "1451227020", "pmid": "30336686", "original_sentence": "Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG are not associated with increased response to _____ in people with Hypercholesterolemia as compared to genotype AA.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["simvastatin"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "ea8bb646-76dd-4862-b03c-c1b78871e0ec", "source_file": "PMC6714829.json", "annotation_id": "1451227020", "pmid": "30336686", "original_sentence": "Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanked_sentence": "Genotypes _____ are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["AG + GG"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "ec38e7f7-2672-4b1a-af1f-742f773b37f8", "source_file": "PMC6714829.json", "annotation_id": "1451227020", "pmid": "30336686", "original_sentence": "Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG are not associated with _____ response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "506523a4-a906-4d71-a048-366b9bf0e49c", "source_file": "PMC6714829.json", "annotation_id": "1451227020", "pmid": "30336686", "original_sentence": "Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG are not associated with increased _____ simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["response to"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "e6a1f119-f4fe-40d2-a482-cd3d2dd50ff8", "source_file": "PMC6714829.json", "annotation_id": "1451227020", "pmid": "30336686", "original_sentence": "Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA.", "blanked_sentence": "Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["AA"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "ce0c1643-bf41-4d38-b93a-46afd669a7fd", "source_file": "PMC8790808.json", "annotation_id": "1451510720", "pmid": "33768542", "original_sentence": "HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["pegaspargase"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "13228b17-3c7f-4a32-82af-50a29192521c", "source_file": "PMC8790808.json", "annotation_id": "1451510720", "pmid": "33768542", "original_sentence": "HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQA1 _____ is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*02:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "7f8ab2a8-a4bc-464a-a55e-fd49bf733762", "source_file": "PMC8790808.json", "annotation_id": "1451510720", "pmid": "33768542", "original_sentence": "HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQA1 *02:01 is associated with _____ risk of Hypersensitivity when treated with pegaspargase.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1c01f247-835e-4661-8a55-9e94f4ac7749", "source_file": "PMC8790808.json", "annotation_id": "1451510720", "pmid": "33768542", "original_sentence": "HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQA1 *02:01 is associated with increased risk of _____ when treated with pegaspargase.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Hypersensitivity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "311f2e26-6059-47c6-b333-38b2d2957be1", "source_file": "PMC8790808.json", "annotation_id": "1451510886", "pmid": "33768542", "original_sentence": "HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["pegaspargase"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "ed6e5f92-a444-4e85-9489-46a872cb36f2", "source_file": "PMC8790808.json", "annotation_id": "1451510886", "pmid": "33768542", "original_sentence": "HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQB1 _____ is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*02:02"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "af0e8a06-e771-4e37-b664-861c88632f3f", "source_file": "PMC8790808.json", "annotation_id": "1451510886", "pmid": "33768542", "original_sentence": "HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQB1 *02:02 is associated with _____ risk of Hypersensitivity when treated with pegaspargase.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "b936ddb8-0718-4da3-b59a-6a58c2fcfa65", "source_file": "PMC8790808.json", "annotation_id": "1451510886", "pmid": "33768542", "original_sentence": "HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DQB1 *02:02 is associated with increased risk of _____ when treated with pegaspargase.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Hypersensitivity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "fe064541-dfd9-4774-be24-fb2b462fd7c7", "source_file": "PMC8790808.json", "annotation_id": "1451510891", "pmid": "33768542", "original_sentence": "HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with _____.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["pegaspargase"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0ee5c2e9-95fc-45da-a8fc-e11bea59c5da", "source_file": "PMC8790808.json", "annotation_id": "1451510891", "pmid": "33768542", "original_sentence": "HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DRB1 _____ is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["*07:01"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "e49ae3b7-3874-4121-a3f9-9dbb227b3c87", "source_file": "PMC8790808.json", "annotation_id": "1451510891", "pmid": "33768542", "original_sentence": "HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DRB1 *07:01 is associated with _____ risk of Hypersensitivity when treated with pegaspargase.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "86fef7f8-ee2f-4938-b8bc-cb1ec75f0f50", "source_file": "PMC8790808.json", "annotation_id": "1451510891", "pmid": "33768542", "original_sentence": "HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.", "blanked_sentence": "HLA-DRB1 *07:01 is associated with increased risk of _____ when treated with pegaspargase.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Hypersensitivity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1c527acc-cca3-44e3-a4a2-a0b0d6641e23", "source_file": "PMC8790808.json", "annotation_id": "1451510773", "pmid": "33768542", "original_sentence": "Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanked_sentence": "Allele T is associated with increased risk of Hypersensitivity when treated with _____ as compared to allele A.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["pegaspargase"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "aa83a6d7-e866-4b14-874e-7a982a5cc6aa", "source_file": "PMC8790808.json", "annotation_id": "1451510773", "pmid": "33768542", "original_sentence": "Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanked_sentence": "Allele _____ is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["T"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "910b8f9f-1877-4986-8a98-2eb5ef170a54", "source_file": "PMC8790808.json", "annotation_id": "1451510773", "pmid": "33768542", "original_sentence": "Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanked_sentence": "Allele T is associated with _____ risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["increased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "0ec9f1d9-19d0-4f67-a63e-2398f198ba48", "source_file": "PMC8790808.json", "annotation_id": "1451510773", "pmid": "33768542", "original_sentence": "Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanked_sentence": "Allele T is associated with increased risk of _____ when treated with pegaspargase as compared to allele A.", "blanks": [{"blanked_field": "Phenotype", "ground_truth": ["Hypersensitivity"], "field_category": "Phenotype"}], "annotation_type": "var_pheno_ann"}
{"question_id": "45d9a673-0b41-4fbd-8e7a-de9d8e66c4cd", "source_file": "PMC8790808.json", "annotation_id": "1451510773", "pmid": "33768542", "original_sentence": "Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanked_sentence": "_____llele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["A"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
{"question_id": "bbee84f4-35cf-4b69-98f5-cb246ff2618c", "source_file": "PMC8973308.json", "annotation_id": "1451768380", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with decreased dose of _____ in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["mercaptopurine"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "22496c10-c415-492e-9109-f6571fa41f21", "source_file": "PMC8973308.json", "annotation_id": "1451768380", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype _____ is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "44a6dd18-b7c8-4cdb-bcfa-d3f2985de678", "source_file": "PMC8973308.json", "annotation_id": "1451768380", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with _____ dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "c7eaae01-7e9a-4dd2-85d9-f06784e73717", "source_file": "PMC8973308.json", "annotation_id": "1451768380", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with decreased _____ mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "fd08a560-bbb7-4bb0-bfc3-7ff5cb182a83", "source_file": "PMC8973308.json", "annotation_id": "1451768380", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "ffd83c81-ef73-46d4-aea4-af83990be1eb", "source_file": "PMC8973308.json", "annotation_id": "1451769040", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with decreased dose of _____ in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["mercaptopurine"], "field_category": "Drug(s)"}], "annotation_type": "var_drug_ann"}
{"question_id": "d9b0abc6-24cb-4747-8102-68c89019973b", "source_file": "PMC8973308.json", "annotation_id": "1451769040", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype _____ is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CT"], "field_category": "Alleles"}], "annotation_type": "var_drug_ann"}
{"question_id": "46d5719a-02cb-46bd-b2f8-98d448dbe483", "source_file": "PMC8973308.json", "annotation_id": "1451769040", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with _____ dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_drug_ann"}
{"question_id": "09eee307-9c06-44db-8761-72fa496f2823", "source_file": "PMC8973308.json", "annotation_id": "1451769040", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with decreased _____ mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "PD/PK terms", "ground_truth": ["dose of"], "field_category": "PD/PK terms"}], "annotation_type": "var_drug_ann"}
{"question_id": "c74f79ca-a71f-471c-bf62-17d198bd408d", "source_file": "PMC8973308.json", "annotation_id": "1451769040", "pmid": "35431360", "original_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_drug_ann"}
{"question_id": "44bac45b-05b8-40a8-bc42-f3fe9ce2cf1f", "source_file": "PMC8973308.json", "annotation_id": "1451769000", "pmid": "35431360", "original_sentence": "Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with _____ in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Drug(s)", "ground_truth": ["mercaptopurine"], "field_category": "Drug(s)"}], "annotation_type": "var_pheno_ann"}
{"question_id": "58d1d7aa-72b4-4544-b01c-55c0d8711dd8", "source_file": "PMC8973308.json", "annotation_id": "1451769000", "pmid": "35431360", "original_sentence": "Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype _____ is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Alleles", "ground_truth": ["CG"], "field_category": "Alleles"}], "annotation_type": "var_pheno_ann"}
{"question_id": "1f95f0d1-cdf6-401e-8873-df31d265f5da", "source_file": "PMC8973308.json", "annotation_id": "1451769000", "pmid": "35431360", "original_sentence": "Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CG is associated with _____ likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanks": [{"blanked_field": "Direction", "ground_truth": ["decreased"], "field_category": "Direction"}], "annotation_type": "var_pheno_ann"}
{"question_id": "9d2fe284-0c6e-403f-8837-d7bc2f26be01", "source_file": "PMC8973308.json", "annotation_id": "1451769000", "pmid": "35431360", "original_sentence": "Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.", "blanked_sentence": "Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype _____.", "blanks": [{"blanked_field": "Comparison", "ground_truth": ["CC"], "field_category": "Comparison"}], "annotation_type": "var_pheno_ann"}
